Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17993748,distribution (t(1/2alpha)),"After i.v. administration of NFLXGA, the distribution (t(1/2alpha)) and elimination half-life (t(1/2beta)) were 0.36 +/- 0.07 h and 7.42 +/- 3.55 h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),h,0.36,3063,DB01059,Norfloxacin
,17993748,elimination half-life (t(1/2beta)),"After i.v. administration of NFLXGA, the distribution (t(1/2alpha)) and elimination half-life (t(1/2beta)) were 0.36 +/- 0.07 h and 7.42 +/- 3.55 h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),h,7.42,3064,DB01059,Norfloxacin
,17993748,volume of distribution of NFLXGA at steady state (Vd(ss)),The volume of distribution of NFLXGA at steady state (Vd(ss)) was 4.66 +/- 1.39 l/kg.,Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),[l] / [kg],4.66,3065,DB01059,Norfloxacin
,17993748,maximal absorption concentration (C(max)),"After p.o. administration of NFLXGA, the maximal absorption concentration (C(max)) was 0.43 +/- 0.06 microg/ ml at 1.36 +/- 0.39 h (T(max)).",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),[μg] / [ml],0.43,3066,DB01059,Norfloxacin
,17993748,T(max),"After p.o. administration of NFLXGA, the maximal absorption concentration (C(max)) was 0.43 +/- 0.06 microg/ ml at 1.36 +/- 0.39 h (T(max)).",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),,1,3067,DB01059,Norfloxacin
,17993748,absorption (t(1/2ka)),"The mean absorption (t(1/2ka)) and elimination half-life (t(1/2beta)) of NFLXGA were 0.78 +/- 0.27 h and 7.13 +/- 1.41 h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),h,0.78,3068,DB01059,Norfloxacin
,17993748,elimination half-life (t(1/2beta)),"The mean absorption (t(1/2ka)) and elimination half-life (t(1/2beta)) of NFLXGA were 0.78 +/- 0.27 h and 7.13 +/- 1.41 h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),h,7.13,3069,DB01059,Norfloxacin
,17993748,systemic bioavailability (F),The mean systemic bioavailability (F) after p.o. administration was 31.10 +/- 15.16%.,Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17993748/),%,31.10,3070,DB01059,Norfloxacin
,19839343,limit of detection,"The limit of detection is 1.5 x 10(-3) x microg x mL(-1), which can be applied to the determination of blood serum samples.",[Determination of Norfloxacin by its enhancement effect on the fluorescence intensity of functionalized CdS nanoparticles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19839343/),[μg] / [ml],1.5 x 10(-3),3908,DB01059,Norfloxacin
,3242584,percentage 12 h renal elimination,"On days 2-7, the mean percentage 12 h renal elimination of norfloxacin was 18.6 +/- 1.47 (mean of 82 separate observations).",Chronic dose urinary and serum pharmacokinetics of norfloxacin in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3242584/),,18.6,7428,DB01059,Norfloxacin
,15862658,recovery,Sample preparation by SPE C18 (Supelclean) with recovery 72% was performed.,High-performance liquid chromatographic determination of ciprofloxacin in plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15862658/),%,72,7654,DB01059,Norfloxacin
,10447831,clearance (Cl),"The clearance (Cl) values were 10.4+/-2.5, 13.2+/-1.9 and 14.2+/-2.1 mL/min/kg (mean +/-SD) in the control (healthy udder) cows and in cows with subclinical and postacute clinical mastitis, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),[ml] / [kg·min],10.4,11870,DB01059,Norfloxacin
,10447831,clearance (Cl),"The clearance (Cl) values were 10.4+/-2.5, 13.2+/-1.9 and 14.2+/-2.1 mL/min/kg (mean +/-SD) in the control (healthy udder) cows and in cows with subclinical and postacute clinical mastitis, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),[ml] / [kg·min],13.2,11871,DB01059,Norfloxacin
,10447831,clearance (Cl),"The clearance (Cl) values were 10.4+/-2.5, 13.2+/-1.9 and 14.2+/-2.1 mL/min/kg (mean +/-SD) in the control (healthy udder) cows and in cows with subclinical and postacute clinical mastitis, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),[ml] / [kg·min],14.2,11872,DB01059,Norfloxacin
,10447831,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss) in the respective groups was 3.1+/-0.7, 2.2+/-0.6 and 1.3+/-0.2 L/kg.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),[l] / [kg],3.1,11873,DB01059,Norfloxacin
,10447831,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss) in the respective groups was 3.1+/-0.7, 2.2+/-0.6 and 1.3+/-0.2 L/kg.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),[l] / [kg],2.2,11874,DB01059,Norfloxacin
,10447831,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss) in the respective groups was 3.1+/-0.7, 2.2+/-0.6 and 1.3+/-0.2 L/kg.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),[l] / [kg],1.3,11875,DB01059,Norfloxacin
,10447831,half-lives (t1/2),"The half-lives (t1/2) and mean residence times (MRT) of norfloxacin were 353, 206 and 115 min (harmonic means) and 306+/-76, 168+/-39 and 95+/-9 min in control cows or in cows with subclinical and postacute clinical mastitis, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),min,353,11876,DB01059,Norfloxacin
,10447831,half-lives (t1/2),"The half-lives (t1/2) and mean residence times (MRT) of norfloxacin were 353, 206 and 115 min (harmonic means) and 306+/-76, 168+/-39 and 95+/-9 min in control cows or in cows with subclinical and postacute clinical mastitis, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),min,306,11877,DB01059,Norfloxacin
,10447831,mean residence times (MRT),"The half-lives (t1/2) and mean residence times (MRT) of norfloxacin were 353, 206 and 115 min (harmonic means) and 306+/-76, 168+/-39 and 95+/-9 min in control cows or in cows with subclinical and postacute clinical mastitis, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),min,115,11878,DB01059,Norfloxacin
,10447831,mean residence times (MRT),"The half-lives (t1/2) and mean residence times (MRT) of norfloxacin were 353, 206 and 115 min (harmonic means) and 306+/-76, 168+/-39 and 95+/-9 min in control cows or in cows with subclinical and postacute clinical mastitis, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),min,306,11879,DB01059,Norfloxacin
,10447831,mean residence times (MRT),"The half-lives (t1/2) and mean residence times (MRT) of norfloxacin were 353, 206 and 115 min (harmonic means) and 306+/-76, 168+/-39 and 95+/-9 min in control cows or in cows with subclinical and postacute clinical mastitis, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),min,168,11880,DB01059,Norfloxacin
,10447831,mean residence times (MRT),"The half-lives (t1/2) and mean residence times (MRT) of norfloxacin were 353, 206 and 115 min (harmonic means) and 306+/-76, 168+/-39 and 95+/-9 min in control cows or in cows with subclinical and postacute clinical mastitis, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),min,95,11881,DB01059,Norfloxacin
,10447831,area under the concentration vs. time curve (AUC),The area under the concentration vs. time curve (AUC) of norfloxacin in milk was 23899+/-6206 mg/L x min in the control cow group.,Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),[mg] / [l·min],23899,11882,DB01059,Norfloxacin
,10447831,AUC,The AUC in milk was significantly lower in the infected udder quarters of the mastitis groups (5075+/-1887 mg/L x min and 7484+/-4645 mg/L x min in the subclinical and the clinical group).,Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),[mg] / [l·min],5075,11883,DB01059,Norfloxacin
,10447831,AUC,The AUC in milk was significantly lower in the infected udder quarters of the mastitis groups (5075+/-1887 mg/L x min and 7484+/-4645 mg/L x min in the subclinical and the clinical group).,Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),[mg] / [l·min],7484,11884,DB01059,Norfloxacin
,10447831,binding,"The binding was concentration dependent and was 19, 13 and 6% at 0.2, 1.0 and 8.4 mg/L, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),%,19,11885,DB01059,Norfloxacin
,10447831,binding,"The binding was concentration dependent and was 19, 13 and 6% at 0.2, 1.0 and 8.4 mg/L, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),%,13,11886,DB01059,Norfloxacin
,10447831,binding,"The binding was concentration dependent and was 19, 13 and 6% at 0.2, 1.0 and 8.4 mg/L, respectively.",Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),%,6,11887,DB01059,Norfloxacin
,10447831,Binding,Binding to milk protein was 46-51% and concentration independent.,Norfloxacin pharmacokinetics in lactating cows with sub-clinical and clinical mastitis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447831/),%,46-51,11888,DB01059,Norfloxacin
,9661000,total urinary recovery,The total urinary recovery of pefloxacin and the active metabolite norfloxacin was 34%.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),%,34,12488,DB01059,Norfloxacin
,9661000,MIC,Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 microgram/ml the UBT was at least 1:4 for 48 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),[μg] / [ml],0.5,12489,DB01059,Norfloxacin
,9661000,UBT,Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 microgram/ml the UBT was at least 1:4 for 48 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),,1,12490,DB01059,Norfloxacin
,9661000,UBTs,The UBTs of both drugs against Klebsiella pneumoniae were at least 1:16 for 72 h.,Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),,1:16,12491,DB01059,Norfloxacin
,9661000,MIC,"The UBTs for Staphylococcus aureus (the MIC for which was 16 micrograms/ml) of both antibiotics were low, and in some of the samples, no bactericidal titers were observed.",Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661000/),[μg] / [ml],16,12492,DB01059,Norfloxacin
,6238932,peak serum level,The mean peak serum level of enoxacin was 3.7 mg/l and attained at a mean time of 1.9 h after administration; the mean peak serum level of norfloxacin was 1.45 mg/l at a mean time of 1.5 h.,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),[mg] / [l],3.7,14886,DB01059,Norfloxacin
,6238932,peak serum level,The mean peak serum level of enoxacin was 3.7 mg/l and attained at a mean time of 1.9 h after administration; the mean peak serum level of norfloxacin was 1.45 mg/l at a mean time of 1.5 h.,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),[mg] / [l],1.45,14887,DB01059,Norfloxacin
,6238932,serum half-lives,The mean serum half-lives were 6.2 h for enoxacin and 3.25 h for norfloxacin.,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),h,6.2,14888,DB01059,Norfloxacin
,6238932,serum half-lives,The mean serum half-lives were 6.2 h for enoxacin and 3.25 h for norfloxacin.,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),h,3.25,14889,DB01059,Norfloxacin
,6238932,maximum levels,Both agents penetrated blister fluid well and reached maximum levels of 2.9 mg/l (for enoxacin) and 1.0 mg/l (for norfloxacin).,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),[mg] / [l],2.9,14890,DB01059,Norfloxacin
,6238932,maximum levels,Both agents penetrated blister fluid well and reached maximum levels of 2.9 mg/l (for enoxacin) and 1.0 mg/l (for norfloxacin).,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),[mg] / [l],1.0,14891,DB01059,Norfloxacin
,6238932,urinary recovery,The 24 h urinary recovery of enoxacin of 61% was about twice that of norfloxacin.,The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238932/),%,61,14892,DB01059,Norfloxacin
,3302879,serum concentration peak,The dosage of 400 mg gave a mean serum concentration peak (11.2 mg/l) and valley (5.4 mg/l) on the second day and a mean dialysate level of 5 mg/l.,[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3302879/),[mg] / [l],11.2,18048,DB01059,Norfloxacin
,3302879,valley,The dosage of 400 mg gave a mean serum concentration peak (11.2 mg/l) and valley (5.4 mg/l) on the second day and a mean dialysate level of 5 mg/l.,[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3302879/),[mg] / [l],5.4,18049,DB01059,Norfloxacin
,3302879,serum concentration (J14),The last mean serum concentration (J14) were 5.5 mg/l (peak) and 2.5 mg/l (valley) and the mean dialysate level was 2.6 mg/l.,[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3302879/),[mg] / [l],5.5,18050,DB01059,Norfloxacin
,3302879,serum concentration (J14),The last mean serum concentration (J14) were 5.5 mg/l (peak) and 2.5 mg/l (valley) and the mean dialysate level was 2.6 mg/l.,[Treatment of peritonitis in kidney failure patients under continuous ambulatory peritoneal dialysis by pefloxacine. Results and pharmacokinetics]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3302879/),[mg] / [l],2.5,18051,DB01059,Norfloxacin
,9413109,F,Norfloxacin was poorly absorbed after oral administration (60 mg.kg-1) in sheep (F = 4.04%).,Age-related differences in norfloxacin pharmacokinetic behaviour following intravenous and oral administration in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9413109/),%,4.04,19902,DB01059,Norfloxacin
,9413109,oral bioavailability,Mean oral bioavailability was 73.51% in lambs (30 mg.kg-1).,Age-related differences in norfloxacin pharmacokinetic behaviour following intravenous and oral administration in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9413109/),%,73.51,19903,DB01059,Norfloxacin
,8908728,peak norfloxacin plasma level,The peak norfloxacin plasma level of 90.52 +/- 3.18 micrograms/ml attained in the probenecid pre-treated febrile goats was higher than that in the febrile (75.46 +/- 0.72 micrograms/ml) or afebrile goats (62.25 +/- 1.23 micrograms/ml).,The effect of induced fever on the biokinetics of norfloxacin and its interaction with probenecid in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8908728/),[μg] / [ml],90.52,20220,DB01059,Norfloxacin
,8908728,peak norfloxacin plasma level,The peak norfloxacin plasma level of 90.52 +/- 3.18 micrograms/ml attained in the probenecid pre-treated febrile goats was higher than that in the febrile (75.46 +/- 0.72 micrograms/ml) or afebrile goats (62.25 +/- 1.23 micrograms/ml).,The effect of induced fever on the biokinetics of norfloxacin and its interaction with probenecid in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8908728/),[μg] / [ml],75.46,20221,DB01059,Norfloxacin
,8908728,peak norfloxacin plasma level,The peak norfloxacin plasma level of 90.52 +/- 3.18 micrograms/ml attained in the probenecid pre-treated febrile goats was higher than that in the febrile (75.46 +/- 0.72 micrograms/ml) or afebrile goats (62.25 +/- 1.23 micrograms/ml).,The effect of induced fever on the biokinetics of norfloxacin and its interaction with probenecid in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8908728/),[μg] / [ml],62.25,20222,DB01059,Norfloxacin
,1881687,Cmin,The Cmin value was 1.2 +/- 0.77 mg/l.,[Diffusion of norfloxacin in epididymal tissue]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881687/),[mg] / [l],1.2,26250,DB01059,Norfloxacin
,3300308,peak serum concentrations,"Following administration of a 400-mg dose, peak serum concentrations of 1.5 to 2.0 micrograms/ml are achieved within one to two hours.",Review of the bioavailability and pharmacokinetics of oral norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300308/),[μg] / [ml],1.5 to 2.0,27661,DB01059,Norfloxacin
,2218417,bioavailability,"Following oral administration, norfloxacin and ciprofloxacin are well absorbed and the bioavailability of ofloxacin is almost 100%.","The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2218417/),%,100,28613,DB01059,Norfloxacin
,2218417,Half-lives,Half-lives of the drugs are 3-6 hours and they may therefore be administrated twice daily.,"The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2218417/),h,3-6,28614,DB01059,Norfloxacin
,8916010,elimination half-life (T1/2),"It was shown that the elimination half-life (T1/2) of norfloxacin at 20 degrees C (10 ppm: 13.95 +/- 1.18 hr, 100 ppm: 11.71 +/- 1.32 hr) was significantly shorter than that at 12 degrees C (10 ppm: 16.61 +/- 1.47 hr, 100 ppm: 16.32 +/- 1.19 hr) in flounders.","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,13.95,36377,DB01059,Norfloxacin
,8916010,elimination half-life (T1/2),"It was shown that the elimination half-life (T1/2) of norfloxacin at 20 degrees C (10 ppm: 13.95 +/- 1.18 hr, 100 ppm: 11.71 +/- 1.32 hr) was significantly shorter than that at 12 degrees C (10 ppm: 16.61 +/- 1.47 hr, 100 ppm: 16.32 +/- 1.19 hr) in flounders.","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,11.71,36378,DB01059,Norfloxacin
,8916010,elimination half-life (T1/2),"It was shown that the elimination half-life (T1/2) of norfloxacin at 20 degrees C (10 ppm: 13.95 +/- 1.18 hr, 100 ppm: 11.71 +/- 1.32 hr) was significantly shorter than that at 12 degrees C (10 ppm: 16.61 +/- 1.47 hr, 100 ppm: 16.32 +/- 1.19 hr) in flounders.","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,16.61,36379,DB01059,Norfloxacin
,8916010,elimination half-life (T1/2),"It was shown that the elimination half-life (T1/2) of norfloxacin at 20 degrees C (10 ppm: 13.95 +/- 1.18 hr, 100 ppm: 11.71 +/- 1.32 hr) was significantly shorter than that at 12 degrees C (10 ppm: 16.61 +/- 1.47 hr, 100 ppm: 16.32 +/- 1.19 hr) in flounders.","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,16.32,36380,DB01059,Norfloxacin
,8916010,Mean residence time (MRT),"Mean residence time (MRT) was calculated at 12 degrees C (10 ppm: 194.87 +/- 29.88 hr, 100 ppm: 1,222.37 +/- 161.45 hr) and 20 degrees C (10 ppm: 168.42 +/- 25.85, 100 ppm: 606.14 +/- 122.75 hr).","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,194.87,36381,DB01059,Norfloxacin
,8916010,Mean residence time (MRT),"Mean residence time (MRT) was calculated at 12 degrees C (10 ppm: 194.87 +/- 29.88 hr, 100 ppm: 1,222.37 +/- 161.45 hr) and 20 degrees C (10 ppm: 168.42 +/- 25.85, 100 ppm: 606.14 +/- 122.75 hr).","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,"1,222.37",36382,DB01059,Norfloxacin
,8916010,Mean residence time (MRT),"Mean residence time (MRT) was calculated at 12 degrees C (10 ppm: 194.87 +/- 29.88 hr, 100 ppm: 1,222.37 +/- 161.45 hr) and 20 degrees C (10 ppm: 168.42 +/- 25.85, 100 ppm: 606.14 +/- 122.75 hr).","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,168.42,36383,DB01059,Norfloxacin
,8916010,Mean residence time (MRT),"Mean residence time (MRT) was calculated at 12 degrees C (10 ppm: 194.87 +/- 29.88 hr, 100 ppm: 1,222.37 +/- 161.45 hr) and 20 degrees C (10 ppm: 168.42 +/- 25.85, 100 ppm: 606.14 +/- 122.75 hr).","Comparative pharmacokinetics and tissue distribution of norfloxacin-glycine acetate in flounder, (Paralichthys olivaceus) at two different temperatures. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8916010/),h,606.14,36384,DB01059,Norfloxacin
,1601962,limit of detection,Determination was possible for ofloxacin over the concentration range 50-2000 ng/ml; the limit of detection was 20 ng/ml.,Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1601962/),[ng] / [ml],20,41000,DB01059,Norfloxacin
,1601962,recovery,The recovery of ofloxacin added to serum was 88.8-101.7% with a coefficient of variation of less than 5.2%.,Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1601962/),%,88.8-101.7,41001,DB01059,Norfloxacin
,3481328,peak serum concentration,"After an oral dose of ofloxacin 400mg, the mean peak serum concentration in 10 elderly patients was 5.5 mg/L and mean renal excretion during 24 hours was 41%.","In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481328/),[mg] / [l],5.5,41593,DB01059,Norfloxacin
,3481328,renal excretion during 24 hours,"After an oral dose of ofloxacin 400mg, the mean peak serum concentration in 10 elderly patients was 5.5 mg/L and mean renal excretion during 24 hours was 41%.","In vitro activity and concentrations in serum, urine, prostatic secretion and adenoma tissue of ofloxacin in urological patients. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481328/),%,41,41594,DB01059,Norfloxacin
,1466505,elimination half-life (t1/2 beta),"For norfloxacin, the elimination half-life (t1/2 beta) and the mean +/- SEM residence time for plasma were 12.8 +/- 0.59 and 15.05 +/- 0.81 hours, respectively, after oral administration and 8.0 +/- 0.3 and 8.71 +/- 0.23 hours, respectively, after IV administration.",Pharmacokinetics of norfloxacin and its N-desethyl- and oxo-metabolites in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466505/),h,12.8,41898,DB01059,Norfloxacin
,1466505,elimination half-life (t1/2 beta),"For norfloxacin, the elimination half-life (t1/2 beta) and the mean +/- SEM residence time for plasma were 12.8 +/- 0.59 and 15.05 +/- 0.81 hours, respectively, after oral administration and 8.0 +/- 0.3 and 8.71 +/- 0.23 hours, respectively, after IV administration.",Pharmacokinetics of norfloxacin and its N-desethyl- and oxo-metabolites in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466505/),h,8.0,41899,DB01059,Norfloxacin
,1466505,residence time,"For norfloxacin, the elimination half-life (t1/2 beta) and the mean +/- SEM residence time for plasma were 12.8 +/- 0.59 and 15.05 +/- 0.81 hours, respectively, after oral administration and 8.0 +/- 0.3 and 8.71 +/- 0.23 hours, respectively, after IV administration.",Pharmacokinetics of norfloxacin and its N-desethyl- and oxo-metabolites in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466505/),h,15.05,41900,DB01059,Norfloxacin
,1466505,residence time,"For norfloxacin, the elimination half-life (t1/2 beta) and the mean +/- SEM residence time for plasma were 12.8 +/- 0.59 and 15.05 +/- 0.81 hours, respectively, after oral administration and 8.0 +/- 0.3 and 8.71 +/- 0.23 hours, respectively, after IV administration.",Pharmacokinetics of norfloxacin and its N-desethyl- and oxo-metabolites in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466505/),h,8.71,41901,DB01059,Norfloxacin
,1466505,Tmax,"After single oral administration, norfloxacin was absorbed rapidly, with Tmax of 0.22 +/- 0.02 hour.",Pharmacokinetics of norfloxacin and its N-desethyl- and oxo-metabolites in broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466505/),h,0.22,41902,DB01059,Norfloxacin
,1466505,Maximal plasma concentration,Maximal plasma concentration was 2.89 +/- 0.20 microgram/ml.,Pharmacokinetics of norfloxacin and its N-desethyl- and oxo-metabolites in broiler chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466505/),[μg] / [ml],2.89,41903,DB01059,Norfloxacin
,1466505,Oral bioavailability,Oral bioavailability of norfloxacin was found to be 57.0 +/- 2.4%.,Pharmacokinetics of norfloxacin and its N-desethyl- and oxo-metabolites in broiler chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466505/),%,57.0,41904,DB01059,Norfloxacin
,2391752,MIC80,"Antibacterial activity of NFLX, nalidixic acid (NA), amoxicillin (AMPC), cefaclor (CCL), erythromycin (EM) and fosfomycin (FOM) against clinically isolated bacteria was examined, and it was found that MIC80 of NFLX against Staphylococcus aureus was 3.13 micrograms/ml, thus NFLX exhibited stronger antimicrobial activity than NA, AMPC, CCL, EM and FOM.",[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),[μg] / [ml],3.13,44058,DB01059,Norfloxacin
,2391752,MIC80,"2. MIC80 of NFLX against Escherichia coli was 0.05 micrograms/ml or lower, thus NFLX showed better activity than NA, AMPC, CCL, EM and FOM.",[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),[μg] / [ml],0.05,44059,DB01059,Norfloxacin
,2391752,peak values of serum concentration,"3. In single oral administration at fasting of NFLX at dose levels of 1.5-2.4 and 2.5-3.4 mg/kg in tablet form mean peak values of serum concentration were 0.32 micrograms/ml reached in 1 hour and 0.38 micrograms/ml in 2 hours, T1/2's obtained were 1.7-4.0 and 2.2-2.9 hours and AUC's were 1.54 +/- 0.52 and 2.02 +/- 0.93 micrograms.hr/ml, respectively.",[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),[μg] / [ml],0.32,44060,DB01059,Norfloxacin
,2391752,peak values of serum concentration,"3. In single oral administration at fasting of NFLX at dose levels of 1.5-2.4 and 2.5-3.4 mg/kg in tablet form mean peak values of serum concentration were 0.32 micrograms/ml reached in 1 hour and 0.38 micrograms/ml in 2 hours, T1/2's obtained were 1.7-4.0 and 2.2-2.9 hours and AUC's were 1.54 +/- 0.52 and 2.02 +/- 0.93 micrograms.hr/ml, respectively.",[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),[μg] / [ml],0.38,44061,DB01059,Norfloxacin
,2391752,T1/2's,"3. In single oral administration at fasting of NFLX at dose levels of 1.5-2.4 and 2.5-3.4 mg/kg in tablet form mean peak values of serum concentration were 0.32 micrograms/ml reached in 1 hour and 0.38 micrograms/ml in 2 hours, T1/2's obtained were 1.7-4.0 and 2.2-2.9 hours and AUC's were 1.54 +/- 0.52 and 2.02 +/- 0.93 micrograms.hr/ml, respectively.",[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),h,1.7-4.0,44062,DB01059,Norfloxacin
,2391752,T1/2's,"3. In single oral administration at fasting of NFLX at dose levels of 1.5-2.4 and 2.5-3.4 mg/kg in tablet form mean peak values of serum concentration were 0.32 micrograms/ml reached in 1 hour and 0.38 micrograms/ml in 2 hours, T1/2's obtained were 1.7-4.0 and 2.2-2.9 hours and AUC's were 1.54 +/- 0.52 and 2.02 +/- 0.93 micrograms.hr/ml, respectively.",[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),h,2.2-2.9,44063,DB01059,Norfloxacin
,2391752,AUC's,"3. In single oral administration at fasting of NFLX at dose levels of 1.5-2.4 and 2.5-3.4 mg/kg in tablet form mean peak values of serum concentration were 0.32 micrograms/ml reached in 1 hour and 0.38 micrograms/ml in 2 hours, T1/2's obtained were 1.7-4.0 and 2.2-2.9 hours and AUC's were 1.54 +/- 0.52 and 2.02 +/- 0.93 micrograms.hr/ml, respectively.",[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),[h·μg] / [ml],1.54,44064,DB01059,Norfloxacin
,2391752,AUC's,"3. In single oral administration at fasting of NFLX at dose levels of 1.5-2.4 and 2.5-3.4 mg/kg in tablet form mean peak values of serum concentration were 0.32 micrograms/ml reached in 1 hour and 0.38 micrograms/ml in 2 hours, T1/2's obtained were 1.7-4.0 and 2.2-2.9 hours and AUC's were 1.54 +/- 0.52 and 2.02 +/- 0.93 micrograms.hr/ml, respectively.",[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),[h·μg] / [ml],2.02,44065,DB01059,Norfloxacin
,2391752,Urinary recovery rates,"Urinary recovery rates of 11.6-46.9%, 13.8-35.4% in 6-8 hours were demonstrated with the 2 ranges of dose levels, respectively.",[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),%,11.6-46.9,44066,DB01059,Norfloxacin
,2391752,Urinary recovery rates,"Urinary recovery rates of 11.6-46.9%, 13.8-35.4% in 6-8 hours were demonstrated with the 2 ranges of dose levels, respectively.",[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),%,13.8-35.4,44067,DB01059,Norfloxacin
,2391752,clinical,"The clinical efficacy rate was 97.1% including 34 cases with excellent results in 28, good in 5 and fair in 1.",[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),%,97.1,44068,DB01059,Norfloxacin
,2391752,bacterial eradication rate,5. The bacterial eradication rate was 96.8% (30/31) with one exception of a Campylobacter jejuni strain.,[Laboratory and clinical studies on norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391752/),%,96.8,44069,DB01059,Norfloxacin
,28603857,terminal half-life,"The terminal half-life for i.v., i.m. and s.c. routes was 3.18, 4.90 and 4.16 hr, respectively.","Pharmacokinetics of norfloxacin after intravenous, intramuscular and subcutaneous administration to rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603857/),h,3.18,45633,DB01059,Norfloxacin
,28603857,terminal half-life,"The terminal half-life for i.v., i.m. and s.c. routes was 3.18, 4.90 and 4.16 hr, respectively.","Pharmacokinetics of norfloxacin after intravenous, intramuscular and subcutaneous administration to rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603857/),h,4.90,45634,DB01059,Norfloxacin
,28603857,terminal half-life,"The terminal half-life for i.v., i.m. and s.c. routes was 3.18, 4.90 and 4.16 hr, respectively.","Pharmacokinetics of norfloxacin after intravenous, intramuscular and subcutaneous administration to rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603857/),h,4.16,45635,DB01059,Norfloxacin
,28603857,Clearance,Clearance value after i.v. dosing was 0.80 L/h·kg.,"Pharmacokinetics of norfloxacin after intravenous, intramuscular and subcutaneous administration to rabbits. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603857/),[l] / [h·kg],0.80,45636,DB01059,Norfloxacin
,28603857,absolute bioavailability,"After i.m. administration, the absolute bioavailability was (mean ± SD) 108.25 ± 12.98% and the Cmax was 3.68 mg/L.","Pharmacokinetics of norfloxacin after intravenous, intramuscular and subcutaneous administration to rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603857/),%,108.25,45637,DB01059,Norfloxacin
,28603857,Cmax,"After i.m. administration, the absolute bioavailability was (mean ± SD) 108.25 ± 12.98% and the Cmax was 3.68 mg/L.","Pharmacokinetics of norfloxacin after intravenous, intramuscular and subcutaneous administration to rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603857/),[mg] / [l],3.68,45638,DB01059,Norfloxacin
,28603857,absolute bioavailability,"After s.c. administration, the absolute bioavailability was (mean ± SD) 84.08 ± 10.36% and the Cmax was 4.28 mg/L.","Pharmacokinetics of norfloxacin after intravenous, intramuscular and subcutaneous administration to rabbits. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603857/),%,84.08,45639,DB01059,Norfloxacin
,28603857,Cmax,"After s.c. administration, the absolute bioavailability was (mean ± SD) 84.08 ± 10.36% and the Cmax was 4.28 mg/L.","Pharmacokinetics of norfloxacin after intravenous, intramuscular and subcutaneous administration to rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603857/),[mg] / [l],4.28,45640,DB01059,Norfloxacin
≤,28603857,MIC,"As general adverse reactions were not observed in any rabbit and favourable pharmacokinetics were found, norfloxacin at 10 mg/kg after i.m. and s.c. dose could be effective in rabbits against micro-organisms with MIC ≤0.14 or 0.11 μg/mL, respectively.","Pharmacokinetics of norfloxacin after intravenous, intramuscular and subcutaneous administration to rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603857/),[μg] / [ml],0.14,45641,DB01059,Norfloxacin
,28603857,MIC,"As general adverse reactions were not observed in any rabbit and favourable pharmacokinetics were found, norfloxacin at 10 mg/kg after i.m. and s.c. dose could be effective in rabbits against micro-organisms with MIC ≤0.14 or 0.11 μg/mL, respectively.","Pharmacokinetics of norfloxacin after intravenous, intramuscular and subcutaneous administration to rabbits. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603857/),[μg] / [ml],0.11,45642,DB01059,Norfloxacin
,7784342,steady-state plasma concentrations,"The effects of norfloxacin (NOR), at steady-state plasma concentrations of 0-32 mg.l-1, on the plasma clearance of a 6 mg.",Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784342/),[mg] / [l],0-32,45925,DB01059,Norfloxacin
,7784342,Ki,"The effects were characterised by a Ki value (Ki = 12 microM), which was comparable with Ki values obtained previously under identical conditions for ciprofloxacin, but higher than that obtained for enoxacin.",Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784342/),μM,12,45926,DB01059,Norfloxacin
,6587830,Half-lives,Half-lives ranged from 1.9 h in mice to 8.6 h in humans.,"Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),h,1.9,46778,DB01059,Norfloxacin
,6587830,Half-lives,Half-lives ranged from 1.9 h in mice to 8.6 h in humans.,"Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),h,8.6,46779,DB01059,Norfloxacin
,6587830,ratios,"The norfloxacin/pefloxacin ratios were 0 in mice, ca. 1 in rats and dogs, 1.6 in cynomolgus monkeys, and 2.3 in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),,0,46780,DB01059,Norfloxacin
,6587830,ratios,"The norfloxacin/pefloxacin ratios were 0 in mice, ca. 1 in rats and dogs, 1.6 in cynomolgus monkeys, and 2.3 in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),,1,46781,DB01059,Norfloxacin
,6587830,ratios,"The norfloxacin/pefloxacin ratios were 0 in mice, ca. 1 in rats and dogs, 1.6 in cynomolgus monkeys, and 2.3 in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),,1.6,46782,DB01059,Norfloxacin
,6587830,ratios,"The norfloxacin/pefloxacin ratios were 0 in mice, ca. 1 in rats and dogs, 1.6 in cynomolgus monkeys, and 2.3 in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),,2,46783,DB01059,Norfloxacin
,6587830,urinary recovery,"The urinary recovery of identified metabolites was 29.5% of the dose in mice, 37.8% in rats, 36.3% in dogs, 26.5% in monkeys, and 58.9% in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),%,29.5,46784,DB01059,Norfloxacin
,6587830,urinary recovery,"The urinary recovery of identified metabolites was 29.5% of the dose in mice, 37.8% in rats, 36.3% in dogs, 26.5% in monkeys, and 58.9% in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),%,37.8,46785,DB01059,Norfloxacin
,6587830,urinary recovery,"The urinary recovery of identified metabolites was 29.5% of the dose in mice, 37.8% in rats, 36.3% in dogs, 26.5% in monkeys, and 58.9% in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),%,36.3,46786,DB01059,Norfloxacin
,6587830,urinary recovery,"The urinary recovery of identified metabolites was 29.5% of the dose in mice, 37.8% in rats, 36.3% in dogs, 26.5% in monkeys, and 58.9% in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),%,26.5,46787,DB01059,Norfloxacin
,6587830,urinary recovery,"The urinary recovery of identified metabolites was 29.5% of the dose in mice, 37.8% in rats, 36.3% in dogs, 26.5% in monkeys, and 58.9% in humans.","Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587830/),%,58.9,46788,DB01059,Norfloxacin
,6230344,maximum serum level,The mean maximum serum level was 1.45 mg/l and occurred 1.5 h after administration.,The pharmacokinetics and tissue penetration of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6230344/),[mg] / [l],1.45,47220,DB01059,Norfloxacin
,6230344,serum half-life,The serum half-life of norfloxacin was found to be 3.5 h.,The pharmacokinetics and tissue penetration of norfloxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6230344/),h,3.5,47221,DB01059,Norfloxacin
,6230344,maximum level,"Rapid blister fluid penetration occurred, the maximum level (occurring between 2-3 h) was about 1 mg/l.",The pharmacokinetics and tissue penetration of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6230344/),[mg] / [l],1,47222,DB01059,Norfloxacin
,3480805,elimination half-life,The mean elimination half-life was significantly increased in the patients (29.0 h) compared to in 8 healthy volunteers (12.3 h).,Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),h,29.0,49933,DB01059,Norfloxacin
,3480805,elimination half-life,The mean elimination half-life was significantly increased in the patients (29.0 h) compared to in 8 healthy volunteers (12.3 h).,Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),h,12.3,49934,DB01059,Norfloxacin
,3480805,total plasma clearance,"In patients, the total plasma clearance (2.71 vs 6.85 l/h) and volume of distribution (1.12 vs 1.67 l/kg) were decreased.",Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),[l] / [h],2.71,49935,DB01059,Norfloxacin
,3480805,total plasma clearance,"In patients, the total plasma clearance (2.71 vs 6.85 l/h) and volume of distribution (1.12 vs 1.67 l/kg) were decreased.",Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),[l] / [h],6.85,49936,DB01059,Norfloxacin
,3480805,volume of distribution,"In patients, the total plasma clearance (2.71 vs 6.85 l/h) and volume of distribution (1.12 vs 1.67 l/kg) were decreased.",Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),[l] / [kg],1.12,49937,DB01059,Norfloxacin
,3480805,volume of distribution,"In patients, the total plasma clearance (2.71 vs 6.85 l/h) and volume of distribution (1.12 vs 1.67 l/kg) were decreased.",Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480805/),[l] / [kg],1.67,49938,DB01059,Norfloxacin
,20662110,flow rate,"A mobile phase solvent consisting of 20 mm sodium dihydrogenphosphate (pH 3.0) and acetonitrile (85:15, v/v) was pumped at a flow rate of 1.0 mL/min.",A simple chromatographic method for determining norfloxacin and enoxacin in pharmacokinetic study assessing CYP1A2 inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20662110/),[ml] / [min],1.0,52340,DB01059,Norfloxacin
,7840567,maximum concentrations,"OPC-17116 showed a high degree of distribution in the lung tissues of both species, with maximum concentrations of 29.6 and 32.0 micrograms/g, respectively.",Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840567/),[μg] / [g],29.6,53129,DB01059,Norfloxacin
,7840567,maximum concentrations,"OPC-17116 showed a high degree of distribution in the lung tissues of both species, with maximum concentrations of 29.6 and 32.0 micrograms/g, respectively.",Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840567/),[μg] / [g],32.0,53130,DB01059,Norfloxacin
<,7840567,MICs,The MICs of this compound for 90% of these organisms except methicillin-resistant S. aureus and P. aeruginosa ranged from < or = 0.006 to 0.78 microgram/ml.,Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840567/),[μg] / [ml],0,53131,DB01059,Norfloxacin
,8721279,flow rate,"The drugs and the internal standard (acebutolol) were eluted from a 4-microns Novapak C-18 cartridge at ambient temperature with an isocratic mobile phase consisting of 14% acetonitrile in buffer solution, at a flow rate of 2.5 ml/min.",Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721279/),[ml] / [min],2.5,57099,DB01059,Norfloxacin
,8721279,Relative recovery,"Relative recovery was 105.5 and 99.5% for pefloxacin and norfloxacin, respectively.",Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721279/),%,105.5,57100,DB01059,Norfloxacin
,8721279,Relative recovery,"Relative recovery was 105.5 and 99.5% for pefloxacin and norfloxacin, respectively.",Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8721279/),%,99.5,57101,DB01059,Norfloxacin
,15501149,MIC(90),The plasma norfloxacin concentrations increased slowly during continuous dosing and reached the MIC(90) (250 ng/mL) for Gram-negative pathogens by 12 h in chickens and 18 h in turkeys.,Disposition of norfloxacin in broiler chickens and turkeys after different methods of oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501149/),[ng] / [ml],250,57571,DB01059,Norfloxacin
,15501149,steady-state plasma concentration,The steady-state plasma concentration was attained in 36 h and remained at approximately 776.67+/-33.23 ng/mL in chickens and 682.50+/-28.55 ng/mL in turkeys.,Disposition of norfloxacin in broiler chickens and turkeys after different methods of oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501149/),[ng] / [ml],776.67,57572,DB01059,Norfloxacin
,15501149,steady-state plasma concentration,The steady-state plasma concentration was attained in 36 h and remained at approximately 776.67+/-33.23 ng/mL in chickens and 682.50+/-28.55 ng/mL in turkeys.,Disposition of norfloxacin in broiler chickens and turkeys after different methods of oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501149/),[ng] / [ml],682.50,57573,DB01059,Norfloxacin
,15501149,half,"Pulse dosing provided half the steady-state concentration that was achieved by continuous dosing, 365.32+/-39.31 ng/mL in chickens and 306.03+/-32.26 ng/mL in turkeys, during the dosing interval of 24 h.",Disposition of norfloxacin in broiler chickens and turkeys after different methods of oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501149/),[ng] / [ml],365.32,57574,DB01059,Norfloxacin
,15501149,steady-state concentration,"Pulse dosing provided half the steady-state concentration that was achieved by continuous dosing, 365.32+/-39.31 ng/mL in chickens and 306.03+/-32.26 ng/mL in turkeys, during the dosing interval of 24 h.",Disposition of norfloxacin in broiler chickens and turkeys after different methods of oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501149/),[ng] / [ml],365.32,57575,DB01059,Norfloxacin
,15501149,steady-state concentration,"Pulse dosing provided half the steady-state concentration that was achieved by continuous dosing, 365.32+/-39.31 ng/mL in chickens and 306.03+/-32.26 ng/mL in turkeys, during the dosing interval of 24 h.",Disposition of norfloxacin in broiler chickens and turkeys after different methods of oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501149/),[ng] / [ml],306.03,57576,DB01059,Norfloxacin
,9624541,peak concentration,"Enoxacin (250 mg/l) demonstrated the highest peak concentration (median) in the urine (0-6 h), followed by ciprofloxacin (237 mg/l) and norfloxacin (157 mg/l) as determined by the HPLC assay.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),[mg] / [l],237,59410,DB01059,Norfloxacin
,9624541,peak concentration,"Enoxacin (250 mg/l) demonstrated the highest peak concentration (median) in the urine (0-6 h), followed by ciprofloxacin (237 mg/l) and norfloxacin (157 mg/l) as determined by the HPLC assay.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),[mg] / [l],157,59411,DB01059,Norfloxacin
,9624541,total amount,"The total amount (mean) excreted by the kidneys as parent drugs were as follows: enoxacin 54% of dose, ciprofloxacin 33% of dose, and norfloxacin 22% of dose.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),,54,59412,DB01059,Norfloxacin
,9624541,total amount,"The total amount (mean) excreted by the kidneys as parent drugs were as follows: enoxacin 54% of dose, ciprofloxacin 33% of dose, and norfloxacin 22% of dose.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),,33,59413,DB01059,Norfloxacin
,9624541,plasma concentrations,"The mean plasma concentrations decreased from 1 to 4 h after administration for enoxacin from 1.9 to 1.4 mg/l, for ciprofloxacin from 2.0 to 0.8 mg/l and for norfloxacin from 1.3 to 0.5 mg/l.",Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9624541/),[mg] / [l],1.9 to 1.4,59414,DB01059,Norfloxacin
,2049424,overall elimination half-life,The overall elimination half-life was 19.9h.,Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049424/),h,19.9,60566,DB01059,Norfloxacin
,2049424,bioavailability,Relative to the IV dose the bioavailability following oral administration of pefloxacin was 76%.,Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049424/),%,76,60567,DB01059,Norfloxacin
,2049424,peritoneal clearance,The peritoneal clearance of pefloxacin averaged 2.5 mL/min.,Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049424/),[ml] / [min],2.5,60568,DB01059,Norfloxacin
,3317294,peak serum concentration,"Its pharmacokinetic properties after a 400-mg oral dose consist of a peak serum concentration of 1.3-1.58 micrograms/ml, an elimination half-life of 3-7 hours, and good penetration into kidney and prostatic tissues.",Norfloxacin: clinical pharmacology and clinical use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317294/),[μg] / [ml],1.3-1.58,60827,DB01059,Norfloxacin
,3317294,elimination half-life,"Its pharmacokinetic properties after a 400-mg oral dose consist of a peak serum concentration of 1.3-1.58 micrograms/ml, an elimination half-life of 3-7 hours, and good penetration into kidney and prostatic tissues.",Norfloxacin: clinical pharmacology and clinical use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317294/),h,3-7,60828,DB01059,Norfloxacin
,6226241,peak plasma levels,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],2.39,63519,DB01059,Norfloxacin
,6226241,peak plasma levels,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],1.63,63520,DB01059,Norfloxacin
,6226241,peak plasma levels,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],5.00,63521,DB01059,Norfloxacin
,6226241,elimination half-lives,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,2.24,63522,DB01059,Norfloxacin
,6226241,elimination half-lives,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,2.81,63523,DB01059,Norfloxacin
,6226241,elimination half-lives,"The mean peak plasma levels of AT-2266 in mice, rats, and dogs (given a single dose of 50 mg/kg for mice and rats and 25 mg/kg for dogs) were 2.39, 1.63, and 5.00 mug/ml, respectively, with elimination half-lives of 2.24, 2.81, and 5.76 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,5.76,63524,DB01059,Norfloxacin
,6226241,elimination half-lives,"The respective mean plasma levels of norfloxacin at similar dosages were 0.510, 0.410, and 0.700 mug/ml; elimination half-lives were 1.40, 2.35, and 6.06 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,1.40,63525,DB01059,Norfloxacin
,6226241,elimination half-lives,"The respective mean plasma levels of norfloxacin at similar dosages were 0.510, 0.410, and 0.700 mug/ml; elimination half-lives were 1.40, 2.35, and 6.06 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,2.35,63526,DB01059,Norfloxacin
,6226241,elimination half-lives,"The respective mean plasma levels of norfloxacin at similar dosages were 0.510, 0.410, and 0.700 mug/ml; elimination half-lives were 1.40, 2.35, and 6.06 h.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),h,6.06,63527,DB01059,Norfloxacin
,6226241,binding rates,"The binding rates of AT-2266 and norfloxacin to plasma of mice, rats, and dogs and to human serum ranged from 27.6 to 40.2% and 39.8 to 44.2%, respectively.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,27.6 to 40.2,63528,DB01059,Norfloxacin
,6226241,binding rates,"The binding rates of AT-2266 and norfloxacin to plasma of mice, rats, and dogs and to human serum ranged from 27.6 to 40.2% and 39.8 to 44.2%, respectively.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,39.8 to 44.2,63529,DB01059,Norfloxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [g·ml·or],2.47,63530,DB01059,Norfloxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [g·ml·or],4.60,63531,DB01059,Norfloxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [g·ml·or],5.35,63532,DB01059,Norfloxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [g·ml·or],33.9,63533,DB01059,Norfloxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],0.234,63534,DB01059,Norfloxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],0.390,63535,DB01059,Norfloxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],0.272,63536,DB01059,Norfloxacin
,6226241,peak levels,"In rats receiving a single dose of 50 mg/kg, the respective mean peak levels of AT-2266 in plasma, lung, muscle, and kidney were 2.47, 4.60, 5.35, and 33.9 mug/ml or g, whereas those of norfloxacin were 0.234, 0.390, 0.272, and 2.05 mug/ml or g.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),[μg] / [ml],2.05,63537,DB01059,Norfloxacin
,6226241,24-,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,56.6,63538,DB01059,Norfloxacin
,6226241,24-,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,40.5,63539,DB01059,Norfloxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,56.6,63540,DB01059,Norfloxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,40.5,63541,DB01059,Norfloxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,64.1,63542,DB01059,Norfloxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,4.40,63543,DB01059,Norfloxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,2.91,63544,DB01059,Norfloxacin
,6226241,recoveries,"The respective 24-h recoveries of AT-2266 from urine of mice, rats, and dogs after single doses of 50, 50, and 25 mg/kg were 56.6, 40.5, and 64.1%, and recoveries of norfloxacin at these doses were 4.40, 2.91, and 5.34%.","Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,5.34,63545,DB01059,Norfloxacin
,6226241,24-h,The respective 24-h recoveries of AT-2266 from bile and feces of rats given a single dose of 50 mg/kg were 2.47 and 52.7%.,"Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,2.47,63546,DB01059,Norfloxacin
,6226241,recoveries,The respective 24-h recoveries of AT-2266 from bile and feces of rats given a single dose of 50 mg/kg were 2.47 and 52.7%.,"Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,2.47,63547,DB01059,Norfloxacin
,6226241,recoveries,The respective 24-h recoveries of AT-2266 from bile and feces of rats given a single dose of 50 mg/kg were 2.47 and 52.7%.,"Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226241/),%,52.7,63548,DB01059,Norfloxacin
,3282749,bioavaila,"With the exception of norfloxacin, which is only 30 to 40% bioavailable from the oral route, the 4-quinolones are 80 to 100% bioavailable, absorption occurring within 1 to 3 hours.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,80 to 100,67687,DB01059,Norfloxacin
greater,3282749,volumes of distribution,"The 4-quinolones are widely distributed throughout the body, with volumes of distribution greater than 1.5 L/kg.",Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),[l] / [kg],1.5,67688,DB01059,Norfloxacin
less,3282749,Protein binding,Protein binding is less than 30% in most cases.,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),%,30,67689,DB01059,Norfloxacin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,3 and 5,67690,DB01059,Norfloxacin
,3282749,Elimination half-lives,Elimination half-lives vary between 3 and 5 hours (ciprofloxacin) and 8 to 14 hours (pefloxacin).,Clinical pharmacokinetics of the newer antibacterial 4-quinolones. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282749/),h,8 to 14,67691,DB01059,Norfloxacin
,3563419,peak serum concentration,"The mean peak serum concentration (+/- SD) attained after 0.75-1.0 h was 0.75 +/- 0.15 mg/l measured by HPLC, and the mean terminal serum half-life was 4.2 +/- 0.6 h.",Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3563419/),[mg] / [l],0.75,68386,DB01059,Norfloxacin
,3563419,terminal serum half-life,"The mean peak serum concentration (+/- SD) attained after 0.75-1.0 h was 0.75 +/- 0.15 mg/l measured by HPLC, and the mean terminal serum half-life was 4.2 +/- 0.6 h.",Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3563419/),h,4.2,68387,DB01059,Norfloxacin
,3563419,cumulative urinary elimination,The mean cumulative urinary elimination was 29% during 12 h after dosing.,Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3563419/),%,29,68388,DB01059,Norfloxacin
,12238145,area under the plasma concentration-time curve (AUC0-->infinity),"The area under the plasma concentration-time curve (AUC0-->infinity) values, after the first dose was administered, for the 30 mg/kg groups given garenoxacin, ciprofloxacin and norfloxacin were 164, 68.1 and 65.7 micrograms.hr/mL, respectively.","Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238145/),[h·μg] / [ml],164,68460,DB01059,Norfloxacin
,12238145,area under the plasma concentration-time curve (AUC0-->infinity),"The area under the plasma concentration-time curve (AUC0-->infinity) values, after the first dose was administered, for the 30 mg/kg groups given garenoxacin, ciprofloxacin and norfloxacin were 164, 68.1 and 65.7 micrograms.hr/mL, respectively.","Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238145/),[h·μg] / [ml],68.1,68461,DB01059,Norfloxacin
,12238145,area under the plasma concentration-time curve (AUC0-->infinity),"The area under the plasma concentration-time curve (AUC0-->infinity) values, after the first dose was administered, for the 30 mg/kg groups given garenoxacin, ciprofloxacin and norfloxacin were 164, 68.1 and 65.7 micrograms.hr/mL, respectively.","Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238145/),[h·μg] / [ml],65.7,68462,DB01059,Norfloxacin
,12238145,AUC0-->infinity,"The AUC0-->infinity values, obtained after the 6th day of antimicrobial administration, were 202 and 173 micrograms.hr/mL for male and female dogs, respectively, from the 50 mg/kg garenoxacin group.","Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238145/),[h·μg] / [ml],202,68463,DB01059,Norfloxacin
,12238145,AUC0-->infinity,"The AUC0-->infinity values, obtained after the 6th day of antimicrobial administration, were 202 and 173 micrograms.hr/mL for male and female dogs, respectively, from the 50 mg/kg garenoxacin group.","Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12238145/),[h·μg] / [ml],173,68464,DB01059,Norfloxacin
,2391751,Mean serum concentrations,"1. Mean serum concentrations of NFLX following oral administration to 3 children at dose levels of 3.2 mg/kg, 3.7 mg/kg and 5.4 mg/kg were, respectively, 0.7 microgram/ml, 0.18 microgram/ml and 0.64 microgram/ml at 2-4 hours.","[Pharmacokinetic, bacteriological and clinical studies in the pediatric field on norfloxacin]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391751/),[μg] / [ml],0.7,69787,DB01059,Norfloxacin
,2391751,Mean serum concentrations,"1. Mean serum concentrations of NFLX following oral administration to 3 children at dose levels of 3.2 mg/kg, 3.7 mg/kg and 5.4 mg/kg were, respectively, 0.7 microgram/ml, 0.18 microgram/ml and 0.64 microgram/ml at 2-4 hours.","[Pharmacokinetic, bacteriological and clinical studies in the pediatric field on norfloxacin]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391751/),[μg] / [ml],0.18,69788,DB01059,Norfloxacin
,2391751,Mean serum concentrations,"1. Mean serum concentrations of NFLX following oral administration to 3 children at dose levels of 3.2 mg/kg, 3.7 mg/kg and 5.4 mg/kg were, respectively, 0.7 microgram/ml, 0.18 microgram/ml and 0.64 microgram/ml at 2-4 hours.","[Pharmacokinetic, bacteriological and clinical studies in the pediatric field on norfloxacin]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391751/),[μg] / [ml],0.64,69789,DB01059,Norfloxacin
,2391751,serum half-lives (T1/2),"Mean serum half-lives (T1/2) of NFLX were 2.5-2.9 hours and mean urinary recovery rates in the first 6 hours after administrations were 7.1-30.7%, depending on dose levels.","[Pharmacokinetic, bacteriological and clinical studies in the pediatric field on norfloxacin]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391751/),h,2.5-2.9,69790,DB01059,Norfloxacin
,2391751,urinary recovery rates,"Mean serum half-lives (T1/2) of NFLX were 2.5-2.9 hours and mean urinary recovery rates in the first 6 hours after administrations were 7.1-30.7%, depending on dose levels.","[Pharmacokinetic, bacteriological and clinical studies in the pediatric field on norfloxacin]. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391751/),%,7.1-30.7,69791,DB01059,Norfloxacin
,2391751,MIC,"MIC of NFLX against Staphylococcus aureus was similar to that of ABPC, 0.39-25 micrograms/ml.","[Pharmacokinetic, bacteriological and clinical studies in the pediatric field on norfloxacin]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391751/),[μg] / [ml],0.39-25,69792,DB01059,Norfloxacin
less,2391751,MIC,MIC of NFLX against Escherichia coli was approximately less than or equal to 0.10 microgram/ml.,"[Pharmacokinetic, bacteriological and clinical studies in the pediatric field on norfloxacin]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391751/),[μg] / [ml],0.10,69793,DB01059,Norfloxacin
less,2391751,MIC,MIC of NFLX against Vibrio parahaemolyticus was less than or equal to 0.10 microgram/ml.,"[Pharmacokinetic, bacteriological and clinical studies in the pediatric field on norfloxacin]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391751/),[μg] / [ml],0.10,69794,DB01059,Norfloxacin
,3458699,elimination (T 1/2 beta),Pefloxacin elimination (T 1/2 beta) increased from 11.00 +/- 2.64 h after the first iv dose to 13.93 +/- 3.58 h after the last iv dose (P less than 0.01).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),h,11.00,70526,DB01059,Norfloxacin
,3458699,elimination (T 1/2 beta),Pefloxacin elimination (T 1/2 beta) increased from 11.00 +/- 2.64 h after the first iv dose to 13.93 +/- 3.58 h after the last iv dose (P less than 0.01).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),h,13.93,70527,DB01059,Norfloxacin
,3458699,Apparent total body clearance,Apparent total body clearance decreased from 148.5 +/- 47.6 to 106.9 +/- 39.2 ml/min (P less than 0.01) because of decreased non-renal clearance (apparent volume of distribution did not significantly change over the repeated pefloxacin administration).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),[ml] / [min],148.5,70528,DB01059,Norfloxacin
,3458699,Apparent total body clearance,Apparent total body clearance decreased from 148.5 +/- 47.6 to 106.9 +/- 39.2 ml/min (P less than 0.01) because of decreased non-renal clearance (apparent volume of distribution did not significantly change over the repeated pefloxacin administration).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),[ml] / [min],106.9,70529,DB01059,Norfloxacin
,3458699,Renal clearance,Renal clearance of pefloxacin was low (7.47 +/- 2.28 ml/min) indicating that non-renal clearance represents the major route of elimination of this quinolone.,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),[ml] / [min],7.47,70530,DB01059,Norfloxacin
,3458699,beta-elimination half-lives,Urinary excretion of pefloxacin and N-desmethyl and N-oxide metabolites was approximately 31% of the pefloxacin dose and beta-elimination half-lives of these metabolites were very close to that of pefloxacin (13.34 +/- 2.72 h and 11.95 +/- 2.64 h respectively).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),h,13.34,70531,DB01059,Norfloxacin
,3458699,beta-elimination half-lives,Urinary excretion of pefloxacin and N-desmethyl and N-oxide metabolites was approximately 31% of the pefloxacin dose and beta-elimination half-lives of these metabolites were very close to that of pefloxacin (13.34 +/- 2.72 h and 11.95 +/- 2.64 h respectively).,Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),h,11.95,70532,DB01059,Norfloxacin
,3458699,accumulation ratio,"Due to a possible saturable process in the metabolic pathway, some accumulation occurred during repeated iv or oral treatment (accumulation ratio = 1.37 +/- 0.20).",Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458699/),,1.37,70533,DB01059,Norfloxacin
,2391750,peak values of serum concentration,"2. After single oral administration of 50 mg and 100 mg NFLX tablet at fasting, mean peak values of serum concentration were 0.35, 0.48 microgram/ml and T1/2 values were 2.2, 2.7 hours, respectively.",[Clinical evaluation of norfloxacin in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391750/),[μg] / [ml],0.35,70639,DB01059,Norfloxacin
,2391750,peak values of serum concentration,"2. After single oral administration of 50 mg and 100 mg NFLX tablet at fasting, mean peak values of serum concentration were 0.35, 0.48 microgram/ml and T1/2 values were 2.2, 2.7 hours, respectively.",[Clinical evaluation of norfloxacin in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391750/),[μg] / [ml],0.48,70640,DB01059,Norfloxacin
,2391750,T1/2,"2. After single oral administration of 50 mg and 100 mg NFLX tablet at fasting, mean peak values of serum concentration were 0.35, 0.48 microgram/ml and T1/2 values were 2.2, 2.7 hours, respectively.",[Clinical evaluation of norfloxacin in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391750/),h,2.2,70641,DB01059,Norfloxacin
,2391750,T1/2,"2. After single oral administration of 50 mg and 100 mg NFLX tablet at fasting, mean peak values of serum concentration were 0.35, 0.48 microgram/ml and T1/2 values were 2.2, 2.7 hours, respectively.",[Clinical evaluation of norfloxacin in children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391750/),h,2.7,70642,DB01059,Norfloxacin
,21554156,polydispersity index,"The results showed that NFX-SLN was spherical and the SLN of the optimized formulation had diameters 301 ± 16.64 nm, polydispersity index 0.15 ± 0.04, zeta potential -30.8 ± 0.69 mv, loading capacity 8.58 ± 0.21% and encapsulation efficiency 92.35 ± 2.24% with good stability at 4 °C.","Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21554156/),,0.15,75991,DB01059,Norfloxacin
,21554156,zeta potential,"The results showed that NFX-SLN was spherical and the SLN of the optimized formulation had diameters 301 ± 16.64 nm, polydispersity index 0.15 ± 0.04, zeta potential -30.8 ± 0.69 mv, loading capacity 8.58 ± 0.21% and encapsulation efficiency 92.35 ± 2.24% with good stability at 4 °C.","Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21554156/),mv,30.8,75992,DB01059,Norfloxacin
,21554156,loading capacity,"The results showed that NFX-SLN was spherical and the SLN of the optimized formulation had diameters 301 ± 16.64 nm, polydispersity index 0.15 ± 0.04, zeta potential -30.8 ± 0.69 mv, loading capacity 8.58 ± 0.21% and encapsulation efficiency 92.35 ± 2.24% with good stability at 4 °C.","Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21554156/),%,8.58,75993,DB01059,Norfloxacin
,21554156,encapsulation efficiency,"The results showed that NFX-SLN was spherical and the SLN of the optimized formulation had diameters 301 ± 16.64 nm, polydispersity index 0.15 ± 0.04, zeta potential -30.8 ± 0.69 mv, loading capacity 8.58 ± 0.21% and encapsulation efficiency 92.35 ± 2.24% with good stability at 4 °C.","Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21554156/),%,92.35,75994,DB01059,Norfloxacin
,21554156,minimum inhibition concentration,"The SLN increased the relative bioavailability of NFX by 12 folds, prolonged the plasma drug level above the average minimum inhibition concentration from 14 to 168 h.","Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21554156/),h,14,75995,DB01059,Norfloxacin
,21554156,minimum inhibition concentration,"The SLN increased the relative bioavailability of NFX by 12 folds, prolonged the plasma drug level above the average minimum inhibition concentration from 14 to 168 h.","Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21554156/),h,168,75996,DB01059,Norfloxacin
,3468102,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax = 1.2 h) and enoxacin the least (Tmax = 1.9 h).,The comparative pharmacokinetics of five quinolones. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,1.2,77966,DB01059,Norfloxacin
,3468102,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax = 1.2 h) and enoxacin the least (Tmax = 1.9 h).,The comparative pharmacokinetics of five quinolones. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,1.9,77967,DB01059,Norfloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,3.75,77968,DB01059,Norfloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,3.9,77969,DB01059,Norfloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,4.0,77970,DB01059,Norfloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,7.0,77971,DB01059,Norfloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,6.2,77972,DB01059,Norfloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,5.1,77973,DB01059,Norfloxacin
,3468102,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h.",The comparative pharmacokinetics of five quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),h,10.5,77974,DB01059,Norfloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,62,77975,DB01059,Norfloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,46.4,77976,DB01059,Norfloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,12.2,77977,DB01059,Norfloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,27,77978,DB01059,Norfloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,30.6,77979,DB01059,Norfloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,75.7,77980,DB01059,Norfloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,73,77981,DB01059,Norfloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,4.9,77982,DB01059,Norfloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,9.2,77983,DB01059,Norfloxacin
,3468102,urine recovery,"The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",The comparative pharmacokinetics of five quinolones. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3468102/),%,17.8,77984,DB01059,Norfloxacin
,3862496,t1/2,"In the patients with cirrhosis, the mean (+/- SD) t1/2, although highly variable, was significantly longer (35.10 +/- 19.00 hours) than in the normal subjects (11.00 +/- 2.64 hours; P less than 0.001).",Pefloxacin kinetics in cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3862496/),h,35.10,79995,DB01059,Norfloxacin
,3862496,t1/2,"In the patients with cirrhosis, the mean (+/- SD) t1/2, although highly variable, was significantly longer (35.10 +/- 19.00 hours) than in the normal subjects (11.00 +/- 2.64 hours; P less than 0.001).",Pefloxacin kinetics in cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3862496/),h,11.00,79996,DB01059,Norfloxacin
,3862496,total plasma clearance,"In the patients, the volume of distribution was decreased by 18% (P less than 0.02) and total plasma clearance was markedly decreased (2.66 +/- 1.85 vs. 8.19 +/- 2.80 L/hr X 1.73 m2; P less than 0.001).",Pefloxacin kinetics in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3862496/),[l] / [1.73·h·m2],2.66,79997,DB01059,Norfloxacin
,3862496,total plasma clearance,"In the patients, the volume of distribution was decreased by 18% (P less than 0.02) and total plasma clearance was markedly decreased (2.66 +/- 1.85 vs. 8.19 +/- 2.80 L/hr X 1.73 m2; P less than 0.001).",Pefloxacin kinetics in cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3862496/),[l] / [1.73·h·m2],8.19,79998,DB01059,Norfloxacin
higher,17917441,Relative bioavailability,Relative bioavailability values calculated for the local and previously developed products relative to Noroxin were higher than 85% based on area under the curve and urinary excretion.,Comparative bioavailability of norfloxacin tablets based on blood and urine data. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17917441/),%,85,82230,DB01059,Norfloxacin
,2262968,peak serum concentration,The mean peak serum concentration of the drug was 0.37 +/- 0.20 micrograms/ml at 2 hours after administration.,[Basic and clinical studies on norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262968/),[μg] / [ml],0.37,82462,DB01059,Norfloxacin
,2262968,half-life,The mean half-life of the drug in serum was 2.8 +/- 0.4 hours and the serum concentration at 8 hours was 0.11 +/- 0.06 micrograms/ml.,[Basic and clinical studies on norfloxacin in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262968/),h,2.8,82463,DB01059,Norfloxacin
,2262968,serum concentration at 8 hours,The mean half-life of the drug in serum was 2.8 +/- 0.4 hours and the serum concentration at 8 hours was 0.11 +/- 0.06 micrograms/ml.,[Basic and clinical studies on norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262968/),[μg] / [ml],0.11,82464,DB01059,Norfloxacin
,2262968,urinary concentration,The mean urinary concentration reached a maximum of 125.2 +2- 166.2 micrograms/ml in pooled urine from 0 to 2 hours and the mean urinary recovery rate in the first 8 hours after administration was 22.1 +/- 6.0%.,[Basic and clinical studies on norfloxacin in the pediatric field]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262968/),[μg] / [ml],125.2,82465,DB01059,Norfloxacin
,2262968,urinary recovery rate,The mean urinary concentration reached a maximum of 125.2 +2- 166.2 micrograms/ml in pooled urine from 0 to 2 hours and the mean urinary recovery rate in the first 8 hours after administration was 22.1 +/- 6.0%.,[Basic and clinical studies on norfloxacin in the pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262968/),%,22.1,82466,DB01059,Norfloxacin
,2262968,overall efficacy rate,"In 62 assessable cases (acute purulent tonsillitis 9 cases, acute pneumonia 3 cases, chronic rhinitis 1 case, urinary tract infections 15 cases, and acute colitis 34 cases), clinical efficacies were excellent in 48 cases, good in 13 cases, and fair in 1 case with an overall efficacy rate of 98.4%.",[Basic and clinical studies on norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262968/),%,98.4,82467,DB01059,Norfloxacin
,3549940,peak serum concentration,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),[μg] / [ml],3.6,82726,DB01059,Norfloxacin
,3549940,peak serum concentrations,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),[μg] / [ml],9.2,82727,DB01059,Norfloxacin
,3549940,peak serum concentrations,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),[μg] / [ml],16.9,82728,DB01059,Norfloxacin
,3549940,half-lives for serum elimination,"Preliminary pharmacokinetic studies in the mouse showed that after a single oral dose of 150 mg/kg ciprofloxacin the peak serum concentration was 3.6 micrograms/ml, and after 50 mg/kg or 150 mg/kg pefloxacin peak serum concentrations were, respectively, 9.2 micrograms/ml and 16.9 micrograms/ml, the half-lives for serum elimination being about 2 hr for both drugs.",Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3549940/),h,2,82729,DB01059,Norfloxacin
,2389884,limit of detection,"Norfloxacin concentration was determined, using high-performance liquid chromatography with a limit of detection of 25 ng of norfloxacin/ml of serum or urine.",Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),ng,25,84195,DB01059,Norfloxacin
,2389884,distribution,"Serum norfloxacin pharmacokinetic values after single IV dosing in dogs were best modeled, using a 2-compartment open model, with distribution and elimination half-lives of 0.467 and 3.56 hours (harmonic means), respectively.",Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),h,0.467,84196,DB01059,Norfloxacin
,2389884,elimination half-lives,"Serum norfloxacin pharmacokinetic values after single IV dosing in dogs were best modeled, using a 2-compartment open model, with distribution and elimination half-lives of 0.467 and 3.56 hours (harmonic means), respectively.",Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),h,3.56,84197,DB01059,Norfloxacin
,2389884,Area-derived volume of distribution (Vd area),"Area-derived volume of distribution (Vd area) was 1.77 +/- 0.69 L/kg (arithmetic mean +/- SD), and serum clearance (Cls) was 0.332 +/- 0.115 L/h/kg.",Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),[l] / [kg],1.77,84198,DB01059,Norfloxacin
,2389884,serum clearance (Cls),"Area-derived volume of distribution (Vd area) was 1.77 +/- 0.69 L/kg (arithmetic mean +/- SD), and serum clearance (Cls) was 0.332 +/- 0.115 L/h/kg.",Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),[l] / [h·kg],0.332,84199,DB01059,Norfloxacin
,2389884,Mean residence time,Mean residence time was 4.32 +/- 0.98 hour.,Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),h,4.32,84200,DB01059,Norfloxacin
,2389884,bioavailability,"Comparison of the area under the curve (AUC; derived, using model-independent calculations) after iv administration (5 mg/kg) with AUC after oral administration (5 mg/kg) in the same dogs indicated bioavailability of 35.0 +/- 46.1%, with a mean residence time after oral administration of 5.71 +/-2.24 hours.",Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),%,35.0,84201,DB01059,Norfloxacin
,2389884,mean residence time,"Comparison of the area under the curve (AUC; derived, using model-independent calculations) after iv administration (5 mg/kg) with AUC after oral administration (5 mg/kg) in the same dogs indicated bioavailability of 35.0 +/- 46.1%, with a mean residence time after oral administration of 5.71 +/-2.24 hours.",Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),h,5.71,84202,DB01059,Norfloxacin
,2389884,Urine concentration,"Urine concentration was 33.8 +/- 15.3 micrograms/ml at 4 hours after a single dose of 5 mg/kg given orally, whereas concentration after 20 mg/kg was given orally was 56.8 +/- 18.0 micrograms/ml at 6 hours after dosing.",Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),[μg] / [ml],33.8,84203,DB01059,Norfloxacin
,2389884,Urine concentration,"Urine concentration was 33.8 +/- 15.3 micrograms/ml at 4 hours after a single dose of 5 mg/kg given orally, whereas concentration after 20 mg/kg was given orally was 56.8 +/- 18.0 micrograms/ml at 6 hours after dosing.",Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),μ,56,84204,DB01059,Norfloxacin
,2389884,urine concentration,"Twelve hours after drug administration, urine concentration was 47.4 +/- 20.6 micrograms/ml after the 5-mg/kg dose and 80.6 +/- 37.7 micrograms/ml after the 20/mg/kg dose.",Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),[μg] / [ml],47.4,84205,DB01059,Norfloxacin
,2389884,urine concentration,"Twelve hours after drug administration, urine concentration was 47.4 +/- 20.6 micrograms/ml after the 5-mg/kg dose and 80.6 +/- 37.7 micrograms/ml after the 20/mg/kg dose.",Pharmacokinetics of norfloxacin in dogs after single intravenous and single and multiple oral administrations of the drug. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389884/),[μg] / [ml],80.6,84206,DB01059,Norfloxacin
,3481335,peak serum level,The mean peak serum level of 6.6 micrograms/ml was attained rapidly 0.8 h after administration.,Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),[μg] / [ml],6.6,85017,DB01059,Norfloxacin
,3481335,serum elimination half-life,The mean serum elimination half-life was 11.6 h.,Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),h,11.6,85018,DB01059,Norfloxacin
,3481335,peak level,Inflammatory fluid was penetrated quickly with a mean peak level of 3.9 micrograms/ml occurring at 2.4 h.,Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),[μg] / [ml],3.9,85019,DB01059,Norfloxacin
,3481335,24 h,"Pefloxacin was excreted in the urine as the parent compound and its two metabolites, norfloxacin and pefloxacin N-oxide (24 h urinary recovery being 8.0%, 12.0% and 13.1% respectively of the dose).",Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),%,8.0,85020,DB01059,Norfloxacin
,3481335,urinary recovery,"Pefloxacin was excreted in the urine as the parent compound and its two metabolites, norfloxacin and pefloxacin N-oxide (24 h urinary recovery being 8.0%, 12.0% and 13.1% respectively of the dose).",Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),%,8.0,85021,DB01059,Norfloxacin
,3481335,urinary recovery,"Pefloxacin was excreted in the urine as the parent compound and its two metabolites, norfloxacin and pefloxacin N-oxide (24 h urinary recovery being 8.0%, 12.0% and 13.1% respectively of the dose).",Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),%,12.0,85022,DB01059,Norfloxacin
,3481335,urinary recovery,"Pefloxacin was excreted in the urine as the parent compound and its two metabolites, norfloxacin and pefloxacin N-oxide (24 h urinary recovery being 8.0%, 12.0% and 13.1% respectively of the dose).",Pharmacokinetics and tissue penetration of orally administered pefloxacin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481335/),%,13.1,85023,DB01059,Norfloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0.53,99479,DB01059,Norfloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0.34,99480,DB01059,Norfloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0. 43,99481,DB01059,Norfloxacin
,10440793,S/P ratios,"The calculated S/P ratios with the influence of absorption eliminated, (S/P)(corr) are: ciprofloxacin 0.53+/-0.02, norfloxacin 0.34+/-0.04, ofloxacin 0. 43+/-0.02 and pefloxacin 0.39+/-0.02 (mean+/-S.E.).",Kinetics of 4-fluoroquinolones permeation into saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440793/),,0.39,99482,DB01059,Norfloxacin
,2391757,peak serum levels,"After administration, peak serum levels of NFLX obtained for the 3 dose levels were 0.16 micrograms/ml at 1 hour, 0.69 micrograms/ml at 2 hours, 0.81 micrograms/ml at 1 hour, respectively, and half-lives were 2.5 hours, 1.8 hours and 2.7 hours, respectively.",[Laboratory and clinical studies of norfloxacin in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),[μg] / [ml],0.16,100670,DB01059,Norfloxacin
,2391757,peak serum levels,"After administration, peak serum levels of NFLX obtained for the 3 dose levels were 0.16 micrograms/ml at 1 hour, 0.69 micrograms/ml at 2 hours, 0.81 micrograms/ml at 1 hour, respectively, and half-lives were 2.5 hours, 1.8 hours and 2.7 hours, respectively.",[Laboratory and clinical studies of norfloxacin in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),[μg] / [ml],0.69,100671,DB01059,Norfloxacin
,2391757,peak serum levels,"After administration, peak serum levels of NFLX obtained for the 3 dose levels were 0.16 micrograms/ml at 1 hour, 0.69 micrograms/ml at 2 hours, 0.81 micrograms/ml at 1 hour, respectively, and half-lives were 2.5 hours, 1.8 hours and 2.7 hours, respectively.",[Laboratory and clinical studies of norfloxacin in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),[μg] / [ml],0.81,100672,DB01059,Norfloxacin
,2391757,half-lives,"After administration, peak serum levels of NFLX obtained for the 3 dose levels were 0.16 micrograms/ml at 1 hour, 0.69 micrograms/ml at 2 hours, 0.81 micrograms/ml at 1 hour, respectively, and half-lives were 2.5 hours, 1.8 hours and 2.7 hours, respectively.",[Laboratory and clinical studies of norfloxacin in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),h,2.5,100673,DB01059,Norfloxacin
,2391757,half-lives,"After administration, peak serum levels of NFLX obtained for the 3 dose levels were 0.16 micrograms/ml at 1 hour, 0.69 micrograms/ml at 2 hours, 0.81 micrograms/ml at 1 hour, respectively, and half-lives were 2.5 hours, 1.8 hours and 2.7 hours, respectively.",[Laboratory and clinical studies of norfloxacin in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),h,1.8,100674,DB01059,Norfloxacin
,2391757,half-lives,"After administration, peak serum levels of NFLX obtained for the 3 dose levels were 0.16 micrograms/ml at 1 hour, 0.69 micrograms/ml at 2 hours, 0.81 micrograms/ml at 1 hour, respectively, and half-lives were 2.5 hours, 1.8 hours and 2.7 hours, respectively.",[Laboratory and clinical studies of norfloxacin in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),h,2.7,100675,DB01059,Norfloxacin
,2391757,peak serum levels,"After administration, mean peak serum levels of NFLX obtained were 1.17 +/- 0.48 micrograms/ml and half-lives were 3.0 +/- 0.5 hours.",[Laboratory and clinical studies of norfloxacin in pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),[μg] / [ml],1.17,100676,DB01059,Norfloxacin
,2391757,half-lives,"After administration, mean peak serum levels of NFLX obtained were 1.17 +/- 0.48 micrograms/ml and half-lives were 3.0 +/- 0.5 hours.",[Laboratory and clinical studies of norfloxacin in pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),h,3.0,100677,DB01059,Norfloxacin
,2391757,Urinary excretion rates,"Urinary excretion rates of NFLX were 14.5% and 28.4% in the first 8 hours after administration of 1.7 mg/kg and 3.2 mg/kg, respectively, and 29.1% in the first 6 hours after administration of 2.4 mg/kg.",[Laboratory and clinical studies of norfloxacin in pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),%,14.5,100678,DB01059,Norfloxacin
,2391757,Urinary excretion rates,"Urinary excretion rates of NFLX were 14.5% and 28.4% in the first 8 hours after administration of 1.7 mg/kg and 3.2 mg/kg, respectively, and 29.1% in the first 6 hours after administration of 2.4 mg/kg.",[Laboratory and clinical studies of norfloxacin in pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),%,28.4,100679,DB01059,Norfloxacin
,2391757,Urinary excretion rates,"Urinary excretion rates of NFLX were 14.5% and 28.4% in the first 8 hours after administration of 1.7 mg/kg and 3.2 mg/kg, respectively, and 29.1% in the first 6 hours after administration of 2.4 mg/kg.",[Laboratory and clinical studies of norfloxacin in pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),%,29.1,100680,DB01059,Norfloxacin
,2391757,urinary excretion rates,Mean urinary excretion rates of NFLX were 38.5 +/- 13.0% in the first 8 hours after administration of 4.4 mg/kg and 4.8 mg/kg.,[Laboratory and clinical studies of norfloxacin in pediatric field]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391757/),%,38.5,100681,DB01059,Norfloxacin
,10096258,inhibition constant (Ki),"In vitro, norfloxacin and pefloxacin competitively inhibited CYP1A2, with inhibition constant (Ki) values of 0.1 and 1 mmol/L, respectively, and CYP1A2 was the only enzyme with a relevant contribution (approximately 50%) to pefloxacin N-4'-demethylation.",Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096258/),[mM] / [l],0.1,101755,DB01059,Norfloxacin
,10096258,inhibition constant (Ki),"In vitro, norfloxacin and pefloxacin competitively inhibited CYP1A2, with inhibition constant (Ki) values of 0.1 and 1 mmol/L, respectively, and CYP1A2 was the only enzyme with a relevant contribution (approximately 50%) to pefloxacin N-4'-demethylation.",Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096258/),[mM] / [l],1,101756,DB01059,Norfloxacin
,7629923,half-life (t1/2 beta),"The intravenous half-life (t1/2 beta) was 209 +/- 36 min, the apparent volume of distribution (Vd(area)) was 3.34 +/- 0.58 L/kg, the total body clearance (ClB) was 1.092 +/- 0.123 x 10(-2) mL/min/kg and the renal clearance (C1R) was 0.411 +/- 0.057 x 10(-2) mL/min/kg.","Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629923/),min,209,105907,DB01059,Norfloxacin
,7629923,apparent volume of distribution (Vd(area)),"The intravenous half-life (t1/2 beta) was 209 +/- 36 min, the apparent volume of distribution (Vd(area)) was 3.34 +/- 0.58 L/kg, the total body clearance (ClB) was 1.092 +/- 0.123 x 10(-2) mL/min/kg and the renal clearance (C1R) was 0.411 +/- 0.057 x 10(-2) mL/min/kg.","Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629923/),[l] / [kg],3.34,105908,DB01059,Norfloxacin
,7629923,total body clearance (ClB),"The intravenous half-life (t1/2 beta) was 209 +/- 36 min, the apparent volume of distribution (Vd(area)) was 3.34 +/- 0.58 L/kg, the total body clearance (ClB) was 1.092 +/- 0.123 x 10(-2) mL/min/kg and the renal clearance (C1R) was 0.411 +/- 0.057 x 10(-2) mL/min/kg.","Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629923/),[ml] / [kg·min],1.092,105909,DB01059,Norfloxacin
,7629923,renal clearance (C1R),"The intravenous half-life (t1/2 beta) was 209 +/- 36 min, the apparent volume of distribution (Vd(area)) was 3.34 +/- 0.58 L/kg, the total body clearance (ClB) was 1.092 +/- 0.123 x 10(-2) mL/min/kg and the renal clearance (C1R) was 0.411 +/- 0.057 x 10(-2) mL/min/kg.","Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629923/),[ml] / [kg·min],0.411,105910,DB01059,Norfloxacin
,7629923,Oral bioavailability,Oral bioavailability was rather poor (9.6% and 6.4% for the 10 and 20 mg/kg doses respectively).,"Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629923/),%,9.6,105911,DB01059,Norfloxacin
,7629923,Oral bioavailability,Oral bioavailability was rather poor (9.6% and 6.4% for the 10 and 20 mg/kg doses respectively).,"Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629923/),%,6.4,105912,DB01059,Norfloxacin
,7629923,intramuscular bioavailability,The intramuscular bioavailability was 31.5% and 18.8% for the 10 and 20 mg/kg doses respectively.,"Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629923/),%,31.5,105913,DB01059,Norfloxacin
,7629923,intramuscular bioavailability,The intramuscular bioavailability was 31.5% and 18.8% for the 10 and 20 mg/kg doses respectively.,"Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7629923/),%,18.8,105914,DB01059,Norfloxacin
,3480804,minimal,"On Day 5 the minimal and maximal plasma concentrations were 5.9 and 11.5 mg.l-1 respectively, after oral administration.",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],5.9,112585,DB01059,Norfloxacin
,3480804,maximal plasma concentrations,"On Day 5 the minimal and maximal plasma concentrations were 5.9 and 11.5 mg.l-1 respectively, after oral administration.",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],11.5,112586,DB01059,Norfloxacin
,3480804,steady-state level,"The steady-state level of the N-desmethyl metabolite ranged from 0.9 (infusion) to 1.2 mg.l-1 (oral route), and that of the N-oxide metabolite ranged from 6.2 (infusion) to 9.0 mg.l-1 (oral route).",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],0.9,112587,DB01059,Norfloxacin
,3480804,steady-state level,"The steady-state level of the N-desmethyl metabolite ranged from 0.9 (infusion) to 1.2 mg.l-1 (oral route), and that of the N-oxide metabolite ranged from 6.2 (infusion) to 9.0 mg.l-1 (oral route).",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],1.2,112588,DB01059,Norfloxacin
,3480804,steady-state level,"The steady-state level of the N-desmethyl metabolite ranged from 0.9 (infusion) to 1.2 mg.l-1 (oral route), and that of the N-oxide metabolite ranged from 6.2 (infusion) to 9.0 mg.l-1 (oral route).",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],6.2,112589,DB01059,Norfloxacin
,3480804,steady-state level,"The steady-state level of the N-desmethyl metabolite ranged from 0.9 (infusion) to 1.2 mg.l-1 (oral route), and that of the N-oxide metabolite ranged from 6.2 (infusion) to 9.0 mg.l-1 (oral route).",Steady-state levels of pefloxacin and its metabolites in patients with severe renal impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3480804/),[mg] / [l],9.0,112590,DB01059,Norfloxacin
,3806953,serum elimination half-life,The mean serum elimination half-life was 8.8 +/- 1.2 hours (standard error) for on- dialysis day and it was 7.0 +/- 0.8 hours for off-dialysis day.,[Human and animal studies on the pharmacokinetics of norfloxacin in renal failure]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806953/),h,8.8,113004,DB01059,Norfloxacin
,3806953,serum elimination half-life,The mean serum elimination half-life was 8.8 +/- 1.2 hours (standard error) for on- dialysis day and it was 7.0 +/- 0.8 hours for off-dialysis day.,[Human and animal studies on the pharmacokinetics of norfloxacin in renal failure]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806953/),h,7.0,113005,DB01059,Norfloxacin
less,3806953,urinary recovery,The urinary recovery of NFLX for 24 hours was less than 0.1% of administered doses in these patients.,[Human and animal studies on the pharmacokinetics of norfloxacin in renal failure]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806953/),%,0.1,113006,DB01059,Norfloxacin
,14603491,total plasma clearance,"By contrast, norfloxacin systemic pharmacokinetics was nonlinear, with total plasma clearance decreasing significantly from 23.0 +/- 3.4 to 14.4 +/- 3.8 mL/min/kg when dose increased from 12.5 to 150 mg/kg.",Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603491/),[ml] / [kg·min],23.0,113561,DB01059,Norfloxacin
,14603491,total plasma clearance,"By contrast, norfloxacin systemic pharmacokinetics was nonlinear, with total plasma clearance decreasing significantly from 23.0 +/- 3.4 to 14.4 +/- 3.8 mL/min/kg when dose increased from 12.5 to 150 mg/kg.",Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603491/),[ml] / [kg·min],14.4,113562,DB01059,Norfloxacin
,3162327,time to maximal serum level,"Orally administered ofloxacin and ciprofloxacin were the most rapidly absorbed (time to maximal serum level, 1.2 hours) and enoxacin the least (1.9 hours).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,1.2,113963,DB01059,Norfloxacin
,3162327,time to maximal serum level,"Orally administered ofloxacin and ciprofloxacin were the most rapidly absorbed (time to maximal serum level, 1.2 hours) and enoxacin the least (1.9 hours).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,1.9,113964,DB01059,Norfloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,3.75,113965,DB01059,Norfloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,3.9,113966,DB01059,Norfloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,4.0,113967,DB01059,Norfloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,7.0,113968,DB01059,Norfloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,6.2,113969,DB01059,Norfloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,5.1,113970,DB01059,Norfloxacin
,3162327,serum elimination half-lives,"The serum elimination half-lives were as follows: norfloxacin, 3.75 hours; ciprofloxacin, 3.9 hours (oral) and 4.0 hours (intravenous); ofloxacin, 7.0 hours; enoxacin, 6.2 hours (oral) and 5.1 hours (intravenous); and pefloxacin, 10.5 hours.",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),h,10.5,113971,DB01059,Norfloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,62,113972,DB01059,Norfloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,46.4,113973,DB01059,Norfloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,12.2,113974,DB01059,Norfloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,27,113975,DB01059,Norfloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,30.6,113976,DB01059,Norfloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,75.7,113977,DB01059,Norfloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,73,113978,DB01059,Norfloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,4.9,113979,DB01059,Norfloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,9.2,113980,DB01059,Norfloxacin
,3162327,24-hour,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,17.8,113981,DB01059,Norfloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,62,113982,DB01059,Norfloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,46.4,113983,DB01059,Norfloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,12.2,113984,DB01059,Norfloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,27,113985,DB01059,Norfloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,30.6,113986,DB01059,Norfloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,75.7,113987,DB01059,Norfloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,73,113988,DB01059,Norfloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,4.9,113989,DB01059,Norfloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,9.2,113990,DB01059,Norfloxacin
,3162327,recovery rate from urine,"The 24-hour recovery rate from urine was 62% for oral enoxacin, 46.4% for intravenous enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for intravenous ciprofloxacin, 73% for ofloxacin, and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).",Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162327/),%,17.8,113991,DB01059,Norfloxacin
,8735421,clearance,Following intravenous administration of 7.5 and 15 mg/kg (calculated as norfloxacin base) the clearance values were 8.5 +/- 2.0 or 7.7 +/- 1.2 mL/min.kg (unweaned calves) and 11.7 +/- 3.2 or 16.1 +/- 3.3 mL/min.kg (weaned calves).,Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),[ml] / [kg·min],8.5,115149,DB01059,Norfloxacin
,8735421,clearance,Following intravenous administration of 7.5 and 15 mg/kg (calculated as norfloxacin base) the clearance values were 8.5 +/- 2.0 or 7.7 +/- 1.2 mL/min.kg (unweaned calves) and 11.7 +/- 3.2 or 16.1 +/- 3.3 mL/min.kg (weaned calves).,Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),[ml] / [kg·min],7.7,115150,DB01059,Norfloxacin
,8735421,clearance,Following intravenous administration of 7.5 and 15 mg/kg (calculated as norfloxacin base) the clearance values were 8.5 +/- 2.0 or 7.7 +/- 1.2 mL/min.kg (unweaned calves) and 11.7 +/- 3.2 or 16.1 +/- 3.3 mL/min.kg (weaned calves).,Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),[ml] / [kg·min],11.7,115151,DB01059,Norfloxacin
,8735421,clearance,Following intravenous administration of 7.5 and 15 mg/kg (calculated as norfloxacin base) the clearance values were 8.5 +/- 2.0 or 7.7 +/- 1.2 mL/min.kg (unweaned calves) and 11.7 +/- 3.2 or 16.1 +/- 3.3 mL/min.kg (weaned calves).,Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),[ml] / [kg·min],16.1,115152,DB01059,Norfloxacin
,8735421,mean residence time,"Norfloxacin mean residence time and volume of distribution values were 211 +/- 33 or 227 +/- 41 min (unweaned calves) and 185 +/- 79 or 128 +/- 18 minutes (weaned calves), and 1.8 +/- 0.3 or 1.7 +/- 0.1 L/kg (unweaned calves) and 2.0 +/- 0.7 or 2.1 +/- 0.7 L/kg (weaned calves) following administration of the lower and higher dose, respectively.",Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),min,211,115153,DB01059,Norfloxacin
,8735421,mean residence time,"Norfloxacin mean residence time and volume of distribution values were 211 +/- 33 or 227 +/- 41 min (unweaned calves) and 185 +/- 79 or 128 +/- 18 minutes (weaned calves), and 1.8 +/- 0.3 or 1.7 +/- 0.1 L/kg (unweaned calves) and 2.0 +/- 0.7 or 2.1 +/- 0.7 L/kg (weaned calves) following administration of the lower and higher dose, respectively.",Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),min,227,115154,DB01059,Norfloxacin
,8735421,mean residence time,"Norfloxacin mean residence time and volume of distribution values were 211 +/- 33 or 227 +/- 41 min (unweaned calves) and 185 +/- 79 or 128 +/- 18 minutes (weaned calves), and 1.8 +/- 0.3 or 1.7 +/- 0.1 L/kg (unweaned calves) and 2.0 +/- 0.7 or 2.1 +/- 0.7 L/kg (weaned calves) following administration of the lower and higher dose, respectively.",Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),[l] / [kg],1.8,115155,DB01059,Norfloxacin
,8735421,volume of distribution,"Norfloxacin mean residence time and volume of distribution values were 211 +/- 33 or 227 +/- 41 min (unweaned calves) and 185 +/- 79 or 128 +/- 18 minutes (weaned calves), and 1.8 +/- 0.3 or 1.7 +/- 0.1 L/kg (unweaned calves) and 2.0 +/- 0.7 or 2.1 +/- 0.7 L/kg (weaned calves) following administration of the lower and higher dose, respectively.",Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),min,227,115156,DB01059,Norfloxacin
,8735421,volume of distribution,"Norfloxacin mean residence time and volume of distribution values were 211 +/- 33 or 227 +/- 41 min (unweaned calves) and 185 +/- 79 or 128 +/- 18 minutes (weaned calves), and 1.8 +/- 0.3 or 1.7 +/- 0.1 L/kg (unweaned calves) and 2.0 +/- 0.7 or 2.1 +/- 0.7 L/kg (weaned calves) following administration of the lower and higher dose, respectively.",Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),min,185,115157,DB01059,Norfloxacin
,8735421,volume of distribution,"Norfloxacin mean residence time and volume of distribution values were 211 +/- 33 or 227 +/- 41 min (unweaned calves) and 185 +/- 79 or 128 +/- 18 minutes (weaned calves), and 1.8 +/- 0.3 or 1.7 +/- 0.1 L/kg (unweaned calves) and 2.0 +/- 0.7 or 2.1 +/- 0.7 L/kg (weaned calves) following administration of the lower and higher dose, respectively.",Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),min,128,115158,DB01059,Norfloxacin
,8735421,volume of distribution,"Norfloxacin mean residence time and volume of distribution values were 211 +/- 33 or 227 +/- 41 min (unweaned calves) and 185 +/- 79 or 128 +/- 18 minutes (weaned calves), and 1.8 +/- 0.3 or 1.7 +/- 0.1 L/kg (unweaned calves) and 2.0 +/- 0.7 or 2.1 +/- 0.7 L/kg (weaned calves) following administration of the lower and higher dose, respectively.",Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),[l] / [kg],1.7,115159,DB01059,Norfloxacin
,8735421,volume of distribution,"Norfloxacin mean residence time and volume of distribution values were 211 +/- 33 or 227 +/- 41 min (unweaned calves) and 185 +/- 79 or 128 +/- 18 minutes (weaned calves), and 1.8 +/- 0.3 or 1.7 +/- 0.1 L/kg (unweaned calves) and 2.0 +/- 0.7 or 2.1 +/- 0.7 L/kg (weaned calves) following administration of the lower and higher dose, respectively.",Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),[l] / [kg],2.0,115160,DB01059,Norfloxacin
,8735421,volume of distribution,"Norfloxacin mean residence time and volume of distribution values were 211 +/- 33 or 227 +/- 41 min (unweaned calves) and 185 +/- 79 or 128 +/- 18 minutes (weaned calves), and 1.8 +/- 0.3 or 1.7 +/- 0.1 L/kg (unweaned calves) and 2.0 +/- 0.7 or 2.1 +/- 0.7 L/kg (weaned calves) following administration of the lower and higher dose, respectively.",Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),[l] / [kg],2.1,115161,DB01059,Norfloxacin
,8735421,bioavailability,Norfloxacin bioavailability following intramuscular administration ranged from 73 to 106%.,Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735421/),%,73 to 106,115162,DB01059,Norfloxacin
,10780965,"C(CSF0, Nor) /","The maximal proconvulsant effect of BPAA is given by the C(CSF0, Nor) / C(CSFbase, Nor) ratio, estimated to approximately 6 in this study.",Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780965/),,6,116630,DB01059,Norfloxacin
,10780965,"C(CSFbase, Nor) ratio","The maximal proconvulsant effect of BPAA is given by the C(CSF0, Nor) / C(CSFbase, Nor) ratio, estimated to approximately 6 in this study.",Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780965/),,6,116631,DB01059,Norfloxacin
,19003804,detection limits,"The obtained detection limits were 2.3x10(-7) mol/L, 5.2x10(-8) mol/L, and 7.8x10(-8) mol/L for ciprofloxacin, norfloxacin, and ofloxacin, respectively.",Determination of quinolone antibiotics in urine by capillary electrophoresis with chemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19003804/),[mol] / [l],2.3x10(-7),117376,DB01059,Norfloxacin
,19003804,detection limits,"The obtained detection limits were 2.3x10(-7) mol/L, 5.2x10(-8) mol/L, and 7.8x10(-8) mol/L for ciprofloxacin, norfloxacin, and ofloxacin, respectively.",Determination of quinolone antibiotics in urine by capillary electrophoresis with chemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19003804/),[mol] / [l],5.2x10(-8),117377,DB01059,Norfloxacin
,19003804,detection limits,"The obtained detection limits were 2.3x10(-7) mol/L, 5.2x10(-8) mol/L, and 7.8x10(-8) mol/L for ciprofloxacin, norfloxacin, and ofloxacin, respectively.",Determination of quinolone antibiotics in urine by capillary electrophoresis with chemiluminescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19003804/),[mol] / [l],7.8x10(-8),117378,DB01059,Norfloxacin
,16958785,total body clearance (Cl(B)),"Multiple doses of OFX significantly reduced the total body clearance (Cl(B)) of TP from 0.117 to 0.085 L/h/kg, although a single dose did not change it.",Effect of ofloxacin on theophylline pharmacokinetics at clinical dosage in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958785/),[l] / [h·kg],0.117,118591,DB01059,Norfloxacin
,16958785,total body clearance (Cl(B)),"Multiple doses of OFX significantly reduced the total body clearance (Cl(B)) of TP from 0.117 to 0.085 L/h/kg, although a single dose did not change it.",Effect of ofloxacin on theophylline pharmacokinetics at clinical dosage in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958785/),[l] / [h·kg],0,118592,DB01059,Norfloxacin
,2760258,T 1/2 h,"The mean (SD) theophylline results were: CL l/kg/h--NOR .038 (.006), C .033 (.006), NAL .045 (.008), P .044 (.007); T 1/2 h--NOR 9.2 (1.8), C 10.6 (1.8), NAL 8.3 (1.8), P 7.5 (1.4).",Effect of quinolone antimicrobials on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760258/),,9.2,119900,DB01059,Norfloxacin
,2760258,T 1/2 h,"The mean (SD) theophylline results were: CL l/kg/h--NOR .038 (.006), C .033 (.006), NAL .045 (.008), P .044 (.007); T 1/2 h--NOR 9.2 (1.8), C 10.6 (1.8), NAL 8.3 (1.8), P 7.5 (1.4).",Effect of quinolone antimicrobials on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760258/),,10.6,119901,DB01059,Norfloxacin
,2760258,T 1/2 h,"The mean (SD) theophylline results were: CL l/kg/h--NOR .038 (.006), C .033 (.006), NAL .045 (.008), P .044 (.007); T 1/2 h--NOR 9.2 (1.8), C 10.6 (1.8), NAL 8.3 (1.8), P 7.5 (1.4).",Effect of quinolone antimicrobials on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2760258/),,8.3,119902,DB01059,Norfloxacin
,2933340,MICs,The MICs of enoxacin against all but one of the gram-negative isolates cultured from 265 urological patients were between 0.03 and 4 mg/l.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.03 and 4,121285,DB01059,Norfloxacin
,2933340,MICs,The MICs against 134 gram-positive isolates were between 0.25 and 16 mg/l except for two strains of streptococci.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.25 and 16,121286,DB01059,Norfloxacin
,2933340,peak serum concentrations,Oral administration of 400 mg of enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],0.7 and 6.3,121287,DB01059,Norfloxacin
,2933340,peak serum concentrations,Oral administration of 400 mg of enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),[mg] / [l],3.6,121288,DB01059,Norfloxacin
,2933340,urinary recovery,The mean urinary recovery of parent drug within 24 h was 31.2% of the administered dose.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2933340/),%,31.2,121289,DB01059,Norfloxacin
,15828341,detection limit,"The linear range was 0.016-0.96 microg x mL(-1), the detection limit was 0.016 microg x mL(-1), the RSD was 1.65%-2.86%, and the recovery was within the range of 99.7%-100.94%.",[The fluorescence characteristics of norfloxacin and its application]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15828341/),[μg] / [ml],0.016,121605,DB01059,Norfloxacin
,15828341,detection limit,"The detection limit was 0.096 microg x mL(-1), the recovery was within the range of 96.24%-104.4% and RSD was 0.71%-2.60%.",[The fluorescence characteristics of norfloxacin and its application]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15828341/),[μg] / [ml],0.096,121606,DB01059,Norfloxacin
,11555178,distribution,"The experimental distribution ratios after i.v. and i.m. administration expressed as area under the concentration-time curve ratios AUC(rumen)/AUC(plasma) were 0.24 and 0.39, respectively, and thus lower than corresponding predicted value of 5.06.",Influence of ruminal distribution on norfloxacin pharmacokinetics in adult sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555178/),,0.24,126227,DB01059,Norfloxacin
,11555178,distribution,"The experimental distribution ratios after i.v. and i.m. administration expressed as area under the concentration-time curve ratios AUC(rumen)/AUC(plasma) were 0.24 and 0.39, respectively, and thus lower than corresponding predicted value of 5.06.",Influence of ruminal distribution on norfloxacin pharmacokinetics in adult sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555178/),,0.39,126228,DB01059,Norfloxacin
,11555178,distribution,"The experimental distribution ratios after i.v. and i.m. administration expressed as area under the concentration-time curve ratios AUC(rumen)/AUC(plasma) were 0.24 and 0.39, respectively, and thus lower than corresponding predicted value of 5.06.",Influence of ruminal distribution on norfloxacin pharmacokinetics in adult sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555178/),,5,126229,DB01059,Norfloxacin
,11555178,mean residence time ratios MRT,"The experimental mean residence time ratios MRT(rumen)/MRT(plasma) after i.v. and i.m. administrations were 2.33 and 1.66, respectively.",Influence of ruminal distribution on norfloxacin pharmacokinetics in adult sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555178/),,2.33,126230,DB01059,Norfloxacin
,11555178,mean residence time ratios MRT,"The experimental mean residence time ratios MRT(rumen)/MRT(plasma) after i.v. and i.m. administrations were 2.33 and 1.66, respectively.",Influence of ruminal distribution on norfloxacin pharmacokinetics in adult sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555178/),,1.66,126231,DB01059,Norfloxacin
,11555178,peak concentrations ratio C(max-rumen)/C(max-plasma),"After p.o. administration, NF concentrations in the rumen content were extremely high compared with the respective plasma concentrations, resulting in mean peak concentrations ratio C(max-rumen)/C(max-plasma) of 383.66 and AUC(rumen)/AUC(plasma) experimental ratio of 402.32.",Influence of ruminal distribution on norfloxacin pharmacokinetics in adult sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555178/),,383.66,126232,DB01059,Norfloxacin
,11555178,AUC(rumen)/AUC,"After p.o. administration, NF concentrations in the rumen content were extremely high compared with the respective plasma concentrations, resulting in mean peak concentrations ratio C(max-rumen)/C(max-plasma) of 383.66 and AUC(rumen)/AUC(plasma) experimental ratio of 402.32.",Influence of ruminal distribution on norfloxacin pharmacokinetics in adult sheep. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555178/),,402.32,126233,DB01059,Norfloxacin
,11555178,distribution ratio,This value was considerably higher (approximately 79 fold) than the predicted distribution ratio of 5.06.,Influence of ruminal distribution on norfloxacin pharmacokinetics in adult sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11555178/),,5.06,126234,DB01059,Norfloxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],0.12,126769,DB01059,Norfloxacin
,17587989,MIC-90,"All the isolates were susceptible to the eight quinolones tested, with an MIC-90 ranging between 0.12 mg/L to 2.0 mg/L depending on the drug.",In vitro activity of eight fluoroquinolones against clinical isolates of Brucella melitensis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587989/),[mg] / [l],2.0,126770,DB01059,Norfloxacin
,3459221,apparent volume of distribution (AVD,The high apparent volume of distribution (AVD = 117 +/- 6 litres) reflects good diffusion in extravascular compartments.,[Pharmacokinetic behavior of pefloxacin in man]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459221/),l,117,128222,DB01059,Norfloxacin
,3459221,elimination half-life,"In subjects with normal liver function, the mean elimination half-life is almost 12 h, which makes it possible to administer pefloxacin twice a day.",[Pharmacokinetic behavior of pefloxacin in man]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459221/),h,12,128223,DB01059,Norfloxacin
,3459221,peak plasma concentrations,"During treatment with 400 mg doses, the steady state is reached within 48 h; mean peak plasma concentrations then are 10 micrograms X ml-1 and mean trough concentrations 4 micrograms X ml-1.",[Pharmacokinetic behavior of pefloxacin in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459221/),[μg] / [ml],10,128224,DB01059,Norfloxacin
,3459221,trough concentrations,"During treatment with 400 mg doses, the steady state is reached within 48 h; mean peak plasma concentrations then are 10 micrograms X ml-1 and mean trough concentrations 4 micrograms X ml-1.",[Pharmacokinetic behavior of pefloxacin in man]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3459221/),[μg] / [ml],4,128225,DB01059,Norfloxacin
,7950332,AUC (area under the curve),"The AUC (area under the curve) for norfloxacin was therefore higher than for ofloxacin (35.9 and 10.7 mg* min/ml, respectively).",Lachrymal concentration of norfloxacin after a single ocular instillation in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7950332/),[mg·min] / [ml],35.9,129483,DB01059,Norfloxacin
,7950332,AUC (area under the curve),"The AUC (area under the curve) for norfloxacin was therefore higher than for ofloxacin (35.9 and 10.7 mg* min/ml, respectively).",Lachrymal concentration of norfloxacin after a single ocular instillation in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7950332/),[mg·min] / [ml],10.7,129484,DB01059,Norfloxacin
,3129392,peak mouse blood levels,Single oral and subcutaneous enoxacin doses (50 mg/kg) gave peak mouse blood levels of 4.9 and 9.5 mg/l and an elimination half-life of 1.8 h.,Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129392/),[mg] / [l],4.9,137480,DB01059,Norfloxacin
,3129392,peak mouse blood levels,Single oral and subcutaneous enoxacin doses (50 mg/kg) gave peak mouse blood levels of 4.9 and 9.5 mg/l and an elimination half-life of 1.8 h.,Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129392/),[mg] / [l],9.5,137481,DB01059,Norfloxacin
,3129392,elimination half-life,Single oral and subcutaneous enoxacin doses (50 mg/kg) gave peak mouse blood levels of 4.9 and 9.5 mg/l and an elimination half-life of 1.8 h.,Enoxacin: in-vitro and animal evaluation as a parenteral and oral agent against hospital bacterial isolates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129392/),h,1.8,137482,DB01059,Norfloxacin
,8863267,log beta 1,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,2.97,141329,DB01059,Norfloxacin
,8863267,log beta 2,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,5.6,141330,DB01059,Norfloxacin
,8863267,log beta 1,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,3.77,141331,DB01059,Norfloxacin
,8863267,log beta 2,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,7.59,141332,DB01059,Norfloxacin
,8863267,log beta 1,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,3.99,141333,DB01059,Norfloxacin
,8863267,log beta 2,"The formation constants of the fluoroquinolones norfloxacin and ciprofloxacin with Mg2+ (log beta 1 = 2.97(4), log beta 2 = 5.6(2)), Zn2+ (log beta 1 = 3.77(2), log beta 2 = 7.59(3)), and Fe2+ (log beta 1 = 3.99(5), log beta 2 = 7.2(5)) were determined by potentiometric titration.",Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863267/),,7.2,141334,DB01059,Norfloxacin
,14733712,corneal,Nalidixic acid had a higher corneal permeability coefficient (17.3 +/- 3.56 x 10(-6) cm/second) than all other drugs tested (p < 0.01).,Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[cm] / [second],17.3,142241,DB01059,Norfloxacin
,14733712,permeability coefficient,Nalidixic acid had a higher corneal permeability coefficient (17.3 +/- 3.56 x 10(-6) cm/second) than all other drugs tested (p < 0.01).,Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[cm] / [second],17.3,142242,DB01059,Norfloxacin
,14733712,perme,"Comparing the corneal and scleral permeability coefficients, only values for nalidixic acid were not significantly different (17.35 +/- 3.56 x l0(-6) cm/second versus 22.69 +/- 5.19 x 10(-6) cm/second, p > 0.05), while all other drugs had scleral permeability coefficients 8 to 10 times greater than corneal permeability coefficients.",Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[cm] / [(l0)^6·second],17.35,142243,DB01059,Norfloxacin
,14733712,perme,"Comparing the corneal and scleral permeability coefficients, only values for nalidixic acid were not significantly different (17.35 +/- 3.56 x l0(-6) cm/second versus 22.69 +/- 5.19 x 10(-6) cm/second, p > 0.05), while all other drugs had scleral permeability coefficients 8 to 10 times greater than corneal permeability coefficients.",Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),,22.69,142244,DB01059,Norfloxacin
,14733712,aqueous humor concentration,"The mean aqueous humor concentration of norfloxacin and ciprofloxacin at 60 minutes to 180 minutes after instillation was around 0.3 microg/mL, a value higher than MIC90 of most bacteria.",Corneal and scleral permeability of quinolones--a pharmacokinetics study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14733712/),[μg] / [ml],0.3,142245,DB01059,Norfloxacin
,8318826,flow-rate,"Following dichloromethane extraction, the solution was chromatographed in a Vydac anion exchange column using a mobile phase of 0.05 M phosphate buffer (pH = 7.0): acetonitrile (80:20, v/v) at a flow-rate of 1.8 mL/min.",A high performance liquid chromatographic procedure for the simultaneous determination of norfloxacin and furprofen in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318826/),[ml] / [min],1.8,145749,DB01059,Norfloxacin
,8318826,total chromatographic analysis time,The total chromatographic analysis time was 10 min.,A high performance liquid chromatographic procedure for the simultaneous determination of norfloxacin and furprofen in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318826/),min,10,145750,DB01059,Norfloxacin
,2712548,relative bioavailabilities,The relative bioavailabilities were 1.8% when norfloxacin was taken with sucralfate and 56.6% when it was taken 2 h after sucralfate.,Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),%,1.8,150390,DB01059,Norfloxacin
,2712548,relative bioavailabilities,The relative bioavailabilities were 1.8% when norfloxacin was taken with sucralfate and 56.6% when it was taken 2 h after sucralfate.,Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),%,56.6,150391,DB01059,Norfloxacin
,2712548,concentrations,"After norfloxacin was given alone, the mean norfloxacin concentrations in urine collected during intervals of 0 to 12, 12 to 24, and 24 to 28 h were 118.9 +/- 72.3, 18.8 +/- 12.5, and 2.4 +/- 2.2 micrograms/ml, respectively.",Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),,18.8,150392,DB01059,Norfloxacin
,2712548,concentrations,"After norfloxacin was given alone, the mean norfloxacin concentrations in urine collected during intervals of 0 to 12, 12 to 24, and 24 to 28 h were 118.9 +/- 72.3, 18.8 +/- 12.5, and 2.4 +/- 2.2 micrograms/ml, respectively.",Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),,2.4,150393,DB01059,Norfloxacin
,2712548,concentrations,"After norfloxacin was given with sucralfate, however, the mean norfloxacin concentrations in urine collected during the same time intervals were 6.8 +/- 4.7, 1.8 +/- 1.4, and 0 +/- 0 microgram/ml, respectively.",Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),,1.8,150394,DB01059,Norfloxacin
,2712548,concentrations,"After norfloxacin was given with sucralfate, however, the mean norfloxacin concentrations in urine collected during the same time intervals were 6.8 +/- 4.7, 1.8 +/- 1.4, and 0 +/- 0 microgram/ml, respectively.",Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),,0,150395,DB01059,Norfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],14,155385,DB01059,Norfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],22,155386,DB01059,Norfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],21,155387,DB01059,Norfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],20,155388,DB01059,Norfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],47,155389,DB01059,Norfloxacin
,8842046,elimination clearance from the CSF,"The elimination clearance from the CSF for norfloxacin, AM-1155, fleroxacin, ofloxacin, sparfloxacin and pefloxacin was 14, 22, 21, 20, 47 and 35 microliters/min/rat, respectively.",Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8842046/),[μl] / [min·rat],35,155390,DB01059,Norfloxacin
,25997556,relative bioavailability,"Finally, the relative bioavailability of NOR after a single oral dosage of 1:5 and 1:10 NOR-CTS was enhanced to 148.02% and 304.98%, respectively.",Chitosan Influences the Expression of P-gp and Metabolism of Norfloxacin in Grass Carp. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25997556/),%,148.02,155523,DB01059,Norfloxacin
,25997556,relative bioavailability,"Finally, the relative bioavailability of NOR after a single oral dosage of 1:5 and 1:10 NOR-CTS was enhanced to 148.02% and 304.98%, respectively.",Chitosan Influences the Expression of P-gp and Metabolism of Norfloxacin in Grass Carp. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25997556/),%,304.98,155524,DB01059,Norfloxacin
,25218157,AUCprostate,"Moxifloxacin showed a significant tissue distribution in the prostate (AUCprostate,ISF/fu·AUCplasma=1.24±0.37), 59% higher than the value obtained for levofloxacin in a previous study.",Enhanced penetration of moxifloxacin into rat prostate tissue evidenced by microdialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25218157/),,1.24,156262,DB01059,Norfloxacin
,2919820,peak serum concentration (Cmax),"When administered at a dosage of 11 mg/kg, the mean peak serum concentration (Cmax) was 1.0 microgram/ml at 1 hour, the time of mean peak concentration (Tmax) after the first dose.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),[μg] / [ml],1.0,156350,DB01059,Norfloxacin
,2919820,Cmax,"After the seventh dose, the Cmax was 1.4 micrograms/ml at Tmax of 1.5 hours.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),[μg] / [ml],1.4,156351,DB01059,Norfloxacin
,2919820,Tmax,"After the seventh dose, the Cmax was 1.4 micrograms/ml at Tmax of 1.5 hours.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),h,1.5,156352,DB01059,Norfloxacin
,2919820,Tmax,"The Tmax for the TCF concentration was 5 hours, with Cmax of 0.3 microgram/ml and 0.7 microgram/ml after the first and seventh dose, respectively.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),h,5,156353,DB01059,Norfloxacin
,2919820,Cmax,"The Tmax for the TCF concentration was 5 hours, with Cmax of 0.3 microgram/ml and 0.7 microgram/ml after the first and seventh dose, respectively.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),[μg] / [ml],0.3,156354,DB01059,Norfloxacin
,2919820,Cmax,"The Tmax for the TCF concentration was 5 hours, with Cmax of 0.3 microgram/ml and 0.7 microgram/ml after the first and seventh dose, respectively.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),[μg] / [ml],0.7,156355,DB01059,Norfloxacin
,2919820,serum Tmax,"When administered at a dosage of 22 mg/kg, the serum Tmax was 2 hours after the first dose, with Cmax of 2.8 micrograms/ml.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),h,2,156356,DB01059,Norfloxacin
,2919820,Cmax,"When administered at a dosage of 22 mg/kg, the serum Tmax was 2 hours after the first dose, with Cmax of 2.8 micrograms/ml.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),[μg] / [ml],2.8,156357,DB01059,Norfloxacin
,2919820,serum Tmax,"After the seventh dose, the serum Tmax was 1.5 hours, with Cmax of 2.8 micrograms/ml.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),h,1.5,156358,DB01059,Norfloxacin
,2919820,Cmax,"After the seventh dose, the serum Tmax was 1.5 hours, with Cmax of 2.8 micrograms/ml.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),[μg] / [ml],2.8,156359,DB01059,Norfloxacin
,2919820,Tmax,"The Tmax for the TCF concentration was 5 hours after the first and seventh doses, with Cmax of 1.2 micrograms/ml and 1.6 micrograms/ml, respectively.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),h,5,156360,DB01059,Norfloxacin
,2919820,Cmax,"The Tmax for the TCF concentration was 5 hours after the first and seventh doses, with Cmax of 1.2 micrograms/ml and 1.6 micrograms/ml, respectively.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),[μg] / [ml],1.2,156361,DB01059,Norfloxacin
,2919820,Cmax,"The Tmax for the TCF concentration was 5 hours after the first and seventh doses, with Cmax of 1.2 micrograms/ml and 1.6 micrograms/ml, respectively.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),[μg] / [ml],1.6,156362,DB01059,Norfloxacin
,2919820,serum elimination half-life,"After the seventh dose, the serum elimination half-life was 6.3 hours for a dosage of 11 mg/kg and was 6.7 hours for a dosage of 22 mg/kg.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),h,6.3,156363,DB01059,Norfloxacin
,2919820,serum elimination half-life,"After the seventh dose, the serum elimination half-life was 6.3 hours for a dosage of 11 mg/kg and was 6.7 hours for a dosage of 22 mg/kg.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),h,6.7,156364,DB01059,Norfloxacin
,2919820,area under the curve from 0 to 12 hours (AUC0----12),"For serum concentration, the area under the curve from 0 to 12 hours (AUC0----12) was 8.77 micrograms.h/ml and 18.27 micrograms.h/ml for dosages of 11 mg/kg and 22 mg/kg, respectively.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),[h·μg] / [ml],8.77,156365,DB01059,Norfloxacin
,2919820,area under the curve from 0 to 12 hours (AUC0----12),"For serum concentration, the area under the curve from 0 to 12 hours (AUC0----12) was 8.77 micrograms.h/ml and 18.27 micrograms.h/ml for dosages of 11 mg/kg and 22 mg/kg, respectively.",Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2919820/),[h·μg] / [ml],18.27,156366,DB01059,Norfloxacin
,25427758,distribution half-life (t1/2α ),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),h,1.58,159351,DB01059,Norfloxacin
,25427758,elimination half-life (t1/2β ),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),h,26.33,159352,DB01059,Norfloxacin
,25427758,elimination half-life (t1/2β ),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),h,1.08,159353,DB01059,Norfloxacin
,25427758,peak concentration (Cmax ),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),h,26.33,159354,DB01059,Norfloxacin
,25427758,time-to-peak concentration (Tmax ),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),h,26.33,159355,DB01059,Norfloxacin
,25427758,time-to-peak concentration (Tmax ),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),[μg] / [l],6069.79,159356,DB01059,Norfloxacin
,25427758,time-to-peak concentration (Tmax ),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),h,1.08,159357,DB01059,Norfloxacin
,25427758,area under the concentration-time curve (AUC),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),[h·μg] / [l],103072.36,159358,DB01059,Norfloxacin
,25427758,area under the concentration-time curve (AUC),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),h,1.36,159359,DB01059,Norfloxacin
,25427758,area under the concentration-time curve (AUC),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),h,26.55,159360,DB01059,Norfloxacin
,25427758,area under the concentration-time curve (AUC),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),[μg] / [l],9586.06,159361,DB01059,Norfloxacin
,25427758,area under the concentration-time curve (AUC),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),h,0.84,159362,DB01059,Norfloxacin
,25427758,area under the concentration-time curve (AUC),"The distribution half-life (t1/2α ), elimination half-life (t1/2β ), peak concentration (Cmax ), time-to-peak concentration (Tmax ), and area under the concentration-time curve (AUC) of common carp were 1.58 h, 26.33 h, 6069.79 μg/L, 1.08 h, and 103072.36 h·μg/L, respectively, and those corresponding to crucian carp were 1.36 h, 26.55 h, 9586.06 μg/L, 0.84 h, and 126604.4 h·μg/L, respectively.",Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25427758/),[h·μg] / [l],126604.4,159363,DB01059,Norfloxacin
,3209530,maximum serum concentration,The mean of the maximum serum concentration of norfloxacin after the first dose was 1.5 mg/l (range 1.1-1.8 mg/l) at a mean of 3.2 h (range 1-6 h).,The pharmacokinetics of norfloxacin in the aged. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209530/),[mg] / [l],1.5,159635,DB01059,Norfloxacin
,3209530,maximum concentration,After the last dose the mean maximum concentration was 2.2 mg/l (range 1.6-3.7 h) at 3 h (range 1-4 h).,The pharmacokinetics of norfloxacin in the aged. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209530/),[mg] / [l],2.2,159636,DB01059,Norfloxacin
,3209530,serum half life,The mean serum half life was 5 h (range 3.7-6.5 h) on day 1 and 5.3 h range (4.4-6.2 h) on day 6.,The pharmacokinetics of norfloxacin in the aged. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209530/),h,5,159637,DB01059,Norfloxacin
,3209530,serum half life,The mean serum half life was 5 h (range 3.7-6.5 h) on day 1 and 5.3 h range (4.4-6.2 h) on day 6.,The pharmacokinetics of norfloxacin in the aged. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209530/),h,5.3,159638,DB01059,Norfloxacin
,3209530,urinary concentrations,Mean urinary concentrations varied between 95 and 288 mg/l from day 1 to day 6.,The pharmacokinetics of norfloxacin in the aged. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3209530/),[mg] / [l],95 and 288,159639,DB01059,Norfloxacin
,3463543,MICs,The MICs of enoxacin against all but one of the gram-negative isolates cultured from 265 urological patients were between 0.03 and 4 mg/l.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.03 and 4,159866,DB01059,Norfloxacin
,3463543,MICs,The MICs against 134 gram-positive isolates were between 0.25 and 16 mg/l except two strains of streptococci.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.25 and 16,159867,DB01059,Norfloxacin
,3463543,peak serum concentrations,Oral administration of 400 mg enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],0.7 and 6.3,159868,DB01059,Norfloxacin
,3463543,peak serum concentrations,Oral administration of 400 mg enoxacin to elderly patients resulted in peak serum concentrations between 0.7 and 6.3 mg/l (mean 3.6 mg/l) attained between 1.0 and 6.0 h following drug ingestion.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),[mg] / [l],3.6,159869,DB01059,Norfloxacin
,3463543,urinary recovery,The mean urinary recovery of parent drug within 24 h was 31.2% of the administered dose.,"In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463543/),%,31.2,159870,DB01059,Norfloxacin
,12110375,K(M),"In human LM, the main metabolite of caffeine was paraxanthine (K(M) 0.4 and 0.5 mmol L(-1)).",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.4,161347,DB01059,Norfloxacin
,12110375,K(M),"In human LM, the main metabolite of caffeine was paraxanthine (K(M) 0.4 and 0.5 mmol L(-1)).",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.5,161348,DB01059,Norfloxacin
,12110375,Apparent K(M),"Apparent K(M) for paraxanthine formation from caffeine in wild-type and CYP1A2-null murine LM were 0.2 and 4.9 mmol L(-1), respectively.",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.2,161349,DB01059,Norfloxacin
,12110375,Apparent K(M),"Apparent K(M) for paraxanthine formation from caffeine in wild-type and CYP1A2-null murine LM were 0.2 and 4.9 mmol L(-1), respectively.",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],4.9,161350,DB01059,Norfloxacin
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.13,161351,DB01059,Norfloxacin
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.2,161352,DB01059,Norfloxacin
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.53,161353,DB01059,Norfloxacin
,24061442,flow rate,"After protein precipitation with acetonitrile:methanol (1:1, vol/vol), satisfactory separation was achieved on a Hypersil BDS C18 column (250 × 4.6 mm, 5 μm) using a mobile phase comprising 20 mM sodium dihydrogen phosphate-2 hydrate (pH = 3.2) and acetonitrile at a ratio of 75:25, vol/vol; the elution was isocratic at ambient temperature with a flow rate of 1.5 mL/min.","Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24061442/),[ml] / [min],1.5,165179,DB01059,Norfloxacin
,2542469,Metabolism,Metabolism is minimal (ca. 15-20% for ciprofloxacin and norfloxacin).,Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),%,15-20,166231,DB01059,Norfloxacin
,2542469,serum half-life,"Because the transintestinal route of elimination compensates for loss of renal elimination, the serum half-life of ciprofloxacvin is raised only to 5-10 hours even in total renal failure.",Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2542469/),h,5-10,166232,DB01059,Norfloxacin
,12507569,distribution (t(1/2alpha)),"After i.v. NFLXGA administration, the distribution (t(1/2alpha)) and elimination half-life (t(1/2beta)) were 0.42 (0.05) and 5.44 (1.36)h.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),h,0.42,166701,DB01059,Norfloxacin
,12507569,elimination half-life (t(1/2beta)),"After i.v. NFLXGA administration, the distribution (t(1/2alpha)) and elimination half-life (t(1/2beta)) were 0.42 (0.05) and 5.44 (1.36)h.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),h,5.44,166702,DB01059,Norfloxacin
,12507569,volume of distribution of NFLXGA at steady state (Vd(ss)),The volume of distribution of NFLXGA at steady state (Vd(ss)) was 2.19 (0.53) Lkg(-1).,Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),1/[lkg],2.19,166703,DB01059,Norfloxacin
,12507569,maximal absorption concentration (C(max)),"After NFLXGA i.m. administration, the maximal absorption concentration (C(max)) was 0.44 (0.04) microgml(-1) at 0.86 (0.15)h (T(max)).",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),1/[μgml],0.44,166704,DB01059,Norfloxacin
,12507569,T(max),"After NFLXGA i.m. administration, the maximal absorption concentration (C(max)) was 0.44 (0.04) microgml(-1) at 0.86 (0.15)h (T(max)).",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),,0,166705,DB01059,Norfloxacin
,12507569,absorption (t(1/2ka)),"The mean absorption (t(1/2ka)) and elimination half-life (t(1/2beta)) of NFLXGA were 0.27 (0.07) and 9.47 (2.24)h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),h,0.27,166706,DB01059,Norfloxacin
,12507569,elimination half-life (t(1/2beta)),"The mean absorption (t(1/2ka)) and elimination half-life (t(1/2beta)) of NFLXGA were 0.27 (0.07) and 9.47 (2.24)h, respectively.",Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),h,9.47,166707,DB01059,Norfloxacin
,12507569,systemic bioavailability (F),The mean systemic bioavailability (F) following i.m. administration was 55 (12)%.,Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507569/),%,55,166708,DB01059,Norfloxacin
,9637308,elimination half-life (T1/2beta),The elimination half-life (T1/2beta) of NFLX (3.37+/-1.37 hr) was not significant as compared with those of NFLXN (3.61+/-0.65 hr) and NFLXGA (3.93+/-1.54 hr).,Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),h,3.37,169592,DB01059,Norfloxacin
,9637308,elimination half-life (T1/2beta),The elimination half-life (T1/2beta) of NFLX (3.37+/-1.37 hr) was not significant as compared with those of NFLXN (3.61+/-0.65 hr) and NFLXGA (3.93+/-1.54 hr).,Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),h,3.61,169593,DB01059,Norfloxacin
,9637308,elimination half-life (T1/2beta),The elimination half-life (T1/2beta) of NFLX (3.37+/-1.37 hr) was not significant as compared with those of NFLXN (3.61+/-0.65 hr) and NFLXGA (3.93+/-1.54 hr).,Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),h,3.93,169594,DB01059,Norfloxacin
,9637308,absolute bioavailability (F),"The absolute bioavailability (F) of NFLX, NFLXN and NFLXGA was calculated as 29%, 45% and 40%.",Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),%,29,169595,DB01059,Norfloxacin
,9637308,absolute bioavailability (F),"The absolute bioavailability (F) of NFLX, NFLXN and NFLXGA was calculated as 29%, 45% and 40%.",Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),%,45,169596,DB01059,Norfloxacin
,9637308,absolute bioavailability (F),"The absolute bioavailability (F) of NFLX, NFLXN and NFLXGA was calculated as 29%, 45% and 40%.",Comparative pharmacokinetic profiles of two norfloxacin formulations after oral administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9637308/),%,40,169597,DB01059,Norfloxacin
,7941848,minimal inhibitory concentrations (MIC's),"The minimal inhibitory concentrations (MIC's) of NFN for a wide range of reference (ATCC-American Type Culture Collection) microbial swine isolates, comprising 21 bacterial and 5 mycoplasmal species, ranged between 0.03 micrograms/ml (for Salmonella cholerasuis and Actinobacillus pleuropneumonia) and 12.5 micrograms/ml (for Streptococcus porcinus).",Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941848/),[μg] / [ml],0.03,170653,DB01059,Norfloxacin
,7941848,minimal inhibitory concentrations (MIC's),"The minimal inhibitory concentrations (MIC's) of NFN for a wide range of reference (ATCC-American Type Culture Collection) microbial swine isolates, comprising 21 bacterial and 5 mycoplasmal species, ranged between 0.03 micrograms/ml (for Salmonella cholerasuis and Actinobacillus pleuropneumonia) and 12.5 micrograms/ml (for Streptococcus porcinus).",Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941848/),[μg] / [ml],12.5,170654,DB01059,Norfloxacin
<,7941848,MIC,"The MIC of NFN for Mycoplasma hyopneumoniae, the causative agent of enzootic pneumonia of pigs, was < 1.0 microgram/ml although M. hyosynoviae was less sensitive, with a MIC value of 3.12 micrograms/ml.",Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941848/),[μg] / [ml],1.0,170655,DB01059,Norfloxacin
,7941848,MIC,"The MIC of NFN for Mycoplasma hyopneumoniae, the causative agent of enzootic pneumonia of pigs, was < 1.0 microgram/ml although M. hyosynoviae was less sensitive, with a MIC value of 3.12 micrograms/ml.",Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941848/),[μg] / [ml],3.12,170656,DB01059,Norfloxacin
,7941848,distribution half-life (t1/2 alpha),"The harmonic mean distribution half-life (t1/2 alpha) and elimination half-life (t1/2 beta) were 4.2 minutes and 2.1 h, respectively.",Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941848/),min,4.2,170657,DB01059,Norfloxacin
,7941848,elimination half-life (t1/2 beta),"The harmonic mean distribution half-life (t1/2 alpha) and elimination half-life (t1/2 beta) were 4.2 minutes and 2.1 h, respectively.",Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941848/),h,2.1,170658,DB01059,Norfloxacin
,7941848,mean residence time (MRT),The mean residence time (MRT) was 2.9 +/- 0.6 h and the steady state volume of distribution (Vss) was 3.2 +/- 0.1 l/kg.,Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941848/),h,2.9,170659,DB01059,Norfloxacin
,7941848,steady state volume of distribution (Vss),The mean residence time (MRT) was 2.9 +/- 0.6 h and the steady state volume of distribution (Vss) was 3.2 +/- 0.1 l/kg.,Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941848/),[l] / [kg],3.2,170660,DB01059,Norfloxacin
,7941848,t1/2 beta,The mean t1/2 beta values after either i. m. or s. c. administration were 4.45 h with very rapid absorption rates (< 15 min to peak plasma drug concentration).,Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941848/),h,4.45,170661,DB01059,Norfloxacin
,7941848,Bioavailability,Bioavailability was 51-64%.,Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7941848/),%,51-64,170662,DB01059,Norfloxacin
,3377462,oral clearance,"However, mean theophylline oral clearance was not significantly different between the two treatments (2.85 +/- 0.68 liters/h without norfloxacin versus 2.56 +/- 0.53 liters/h with norfloxacin [P = 0.08]).",Effect of norfloxacin on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377462/),[l] / [h],2.85,172631,DB01059,Norfloxacin
,3377462,oral clearance,"However, mean theophylline oral clearance was not significantly different between the two treatments (2.85 +/- 0.68 liters/h without norfloxacin versus 2.56 +/- 0.53 liters/h with norfloxacin [P = 0.08]).",Effect of norfloxacin on theophylline pharmacokinetics at steady state. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3377462/),[l] / [h],2.56,172632,DB01059,Norfloxacin
,7674459,tmax,"After single i.m. administration, norfloxacin was absorbed rapidly, with a tmax of 1.46 +/- 0.06 h.",Pharmacokinetics and tissue residues of norfloxacin and its N-desethyl- and oxo-metabolites in healthy pigs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674459/),h,1.46,177911,DB01059,Norfloxacin
,7674459,elimination half-life (t1/2 beta),"The elimination half-life (t1/2 beta) and the mean residence time of norfloxacin in plasma were 4.99 +/- 0.28 and 6.05 +/- 0.22 h, respectively, after i.m. administration and 3.65 +/- 0.16 and 3.34 +/- 0.16 h, respectively, after i.v. administration.",Pharmacokinetics and tissue residues of norfloxacin and its N-desethyl- and oxo-metabolites in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674459/),h,4.99,177912,DB01059,Norfloxacin
,7674459,elimination half-life (t1/2 beta),"The elimination half-life (t1/2 beta) and the mean residence time of norfloxacin in plasma were 4.99 +/- 0.28 and 6.05 +/- 0.22 h, respectively, after i.m. administration and 3.65 +/- 0.16 and 3.34 +/- 0.16 h, respectively, after i.v. administration.",Pharmacokinetics and tissue residues of norfloxacin and its N-desethyl- and oxo-metabolites in healthy pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674459/),h,3.65,177913,DB01059,Norfloxacin
,7674459,mean residence time,"The elimination half-life (t1/2 beta) and the mean residence time of norfloxacin in plasma were 4.99 +/- 0.28 and 6.05 +/- 0.22 h, respectively, after i.m. administration and 3.65 +/- 0.16 and 3.34 +/- 0.16 h, respectively, after i.v. administration.",Pharmacokinetics and tissue residues of norfloxacin and its N-desethyl- and oxo-metabolites in healthy pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674459/),h,6.05,177914,DB01059,Norfloxacin
,7674459,mean residence time,"The elimination half-life (t1/2 beta) and the mean residence time of norfloxacin in plasma were 4.99 +/- 0.28 and 6.05 +/- 0.22 h, respectively, after i.m. administration and 3.65 +/- 0.16 and 3.34 +/- 0.16 h, respectively, after i.v. administration.",Pharmacokinetics and tissue residues of norfloxacin and its N-desethyl- and oxo-metabolites in healthy pigs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674459/),h,3.34,177915,DB01059,Norfloxacin
,7674459,Intramuscular bioavailability,Intramuscular bioavailability was found to be 53.7 +/- 4.4%.,Pharmacokinetics and tissue residues of norfloxacin and its N-desethyl- and oxo-metabolites in healthy pigs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674459/),%,53.7,177916,DB01059,Norfloxacin
greater,7674459,Plasma concentrations,Plasma concentrations greater than 0.2 microgram/mL were achieved at 20 min and persisted up to 8 h post-administration.,Pharmacokinetics and tissue residues of norfloxacin and its N-desethyl- and oxo-metabolites in healthy pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674459/),[μg] / [ml],0.2,177917,DB01059,Norfloxacin
,7674459,Maximal plasma concentration,Maximal plasma concentration was 1.11 +/- 0.03 micrograms/mL.,Pharmacokinetics and tissue residues of norfloxacin and its N-desethyl- and oxo-metabolites in healthy pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674459/),[μg] / [ml],1.11,177918,DB01059,Norfloxacin
,2202843,peak levels,"Mean serum drug concentrations for the 3 dosage groups were at peak levels of 0.27, 0.64 and 1.51 micrograms/ml at 4, 2 and 1 hour(s) after administration, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.27,183350,DB01059,Norfloxacin
,2202843,peak levels,"Mean serum drug concentrations for the 3 dosage groups were at peak levels of 0.27, 0.64 and 1.51 micrograms/ml at 4, 2 and 1 hour(s) after administration, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.64,183351,DB01059,Norfloxacin
,2202843,peak levels,"Mean serum drug concentrations for the 3 dosage groups were at peak levels of 0.27, 0.64 and 1.51 micrograms/ml at 4, 2 and 1 hour(s) after administration, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],1.51,183352,DB01059,Norfloxacin
,2202843,Tmax,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),h,3.0,183353,DB01059,Norfloxacin
,2202843,Tmax,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),h,1.2,183354,DB01059,Norfloxacin
,2202843,Cmax,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.32,183355,DB01059,Norfloxacin
,2202843,Cmax,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.78,183356,DB01059,Norfloxacin
,2202843,Cmax,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],1.56,183357,DB01059,Norfloxacin
,2202843,serum half-lives,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),h,2.2,183358,DB01059,Norfloxacin
,2202843,serum half-lives,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),h,2.4,183359,DB01059,Norfloxacin
,2202843,serum half-lives,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),h,2.3,183360,DB01059,Norfloxacin
,2202843,AUCs,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[h·μg] / [ml],1.65,183361,DB01059,Norfloxacin
,2202843,AUCs,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[h·μg] / [ml],3.98,183362,DB01059,Norfloxacin
,2202843,AUCs,"Pharmacokinetic parameters for these dosage groups were as follows: Tmax values were 3.0, 3.0 and 1.2 hours; Cmax values were 0.32, 0.78 and 1.56 micrograms/ml; serum half-lives were 2.2, 2.4 and 2.3 hours; and AUCs were 1.65, 3.98 and 6.06 micrograms.hr/ml, respectively.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[h·μg] / [ml],6.06,183363,DB01059,Norfloxacin
,2202843,peak urinary drug concentrations,"2. Mean peak urinary drug concentrations for the 3 dosage groups were 45.8, 109.2 and 215.1 micrograms/ml, respectively, and the peaks appeared 2-4 hours after administration.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],45.8,183364,DB01059,Norfloxacin
,2202843,peak urinary drug concentrations,"2. Mean peak urinary drug concentrations for the 3 dosage groups were 45.8, 109.2 and 215.1 micrograms/ml, respectively, and the peaks appeared 2-4 hours after administration.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],109.2,183365,DB01059,Norfloxacin
,2202843,peak urinary drug concentrations,"2. Mean peak urinary drug concentrations for the 3 dosage groups were 45.8, 109.2 and 215.1 micrograms/ml, respectively, and the peaks appeared 2-4 hours after administration.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],215.1,183366,DB01059,Norfloxacin
,2202843,recovery rates,"Mean recovery rates up to 8 hours after administration were 18.3%, 24.5% and 28.7%, respectively for the 3 dosages.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),%,18.3,183367,DB01059,Norfloxacin
,2202843,recovery rates,"Mean recovery rates up to 8 hours after administration were 18.3%, 24.5% and 28.7%, respectively for the 3 dosages.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),%,24.5,183368,DB01059,Norfloxacin
,2202843,recovery rates,"Mean recovery rates up to 8 hours after administration were 18.3%, 24.5% and 28.7%, respectively for the 3 dosages.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),%,28.7,183369,DB01059,Norfloxacin
,2202843,MIC,"3. In a drug sensitivity test against 128 strains of S. sonnei, the most frequent MIC value of NFLX was 0.78 micrograms/ml against 65 strains, followed by 0.39 micrograms/ml for 56 strains.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.78,183370,DB01059,Norfloxacin
,2202843,MIC,"3. In a drug sensitivity test against 128 strains of S. sonnei, the most frequent MIC value of NFLX was 0.78 micrograms/ml against 65 strains, followed by 0.39 micrograms/ml for 56 strains.",[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),[μg] / [ml],0.39,183371,DB01059,Norfloxacin
,2202843,Clinical,4. Clinical efficacy rate of NFLX against bacillary dysentery was 95.2% in 21 cases in which the evaluation was possible.,[Pharmacokinetics and clinical studies of norfloxacin in the pediatric field]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2202843/),,95,183372,DB01059,Norfloxacin
,1864290,penetration,"The penetration of ciprofloxacin into the vitreous humor, based primarily on the data from one report, is about 20%.",Use of quinolones for treatment of ear and eye infections. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1864290/),%,20,188476,DB01059,Norfloxacin
,15155539,AUC ratio,"Brain ECF norfloxacin concentrations were much lower than plasma levels (AUC ratio=9.7+/-2.8%) but peaked very early, and concentration versus time profiles were parallel in both biological fluids.",Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15155539/),%,9.7,190104,DB01059,Norfloxacin
,8233640,serum levels,CPD serum levels at 2 hours after the first dose of treatment showed a median of 2.7 mg/l (2.3-3.4 range).,Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8233640/),[mg] / [l],2.7,191481,DB01059,Norfloxacin
,8233640,MIC,"Bactericidal serum titers at the same time against the patients own strain and an E. coli TEM-1 hyperproducer strain (MIC 4,096 mg/l for ampicillin and 0.5 mg/l for CPD) showed a median value of 1/8 against patients strains and 1/2 against the THP strain.",Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8233640/),[mg] / [l],"4,096",191482,DB01059,Norfloxacin
,8233640,MIC,"Bactericidal serum titers at the same time against the patients own strain and an E. coli TEM-1 hyperproducer strain (MIC 4,096 mg/l for ampicillin and 0.5 mg/l for CPD) showed a median value of 1/8 against patients strains and 1/2 against the THP strain.",Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8233640/),[mg] / [l],0.5,191483,DB01059,Norfloxacin
,28596959,elimination half-life (t½β),"For pefloxacin, the elimination half-life (t½β) was 8.44 ± 0.48 and 13.18 ± 0.82 h after IV and oral administration, respectively.",Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),h,8.44,193133,DB01059,Norfloxacin
,28596959,elimination half-life (t½β),"For pefloxacin, the elimination half-life (t½β) was 8.44 ± 0.48 and 13.18 ± 0.82 h after IV and oral administration, respectively.",Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),h,13.18,193134,DB01059,Norfloxacin
,28596959,absorption half-life (t½a),"After single oral dose, pefloxacin was rapidly absorbed with an absorption half-life (t½a) and TMAX of 0.87 ± 0.07 and 2.01 ± 0.12 h, respectively.",Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),h,0.87,193135,DB01059,Norfloxacin
,28596959,TMAX,"After single oral dose, pefloxacin was rapidly absorbed with an absorption half-life (t½a) and TMAX of 0.87 ± 0.07 and 2.01 ± 0.12 h, respectively.",Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),h,2.01,193136,DB01059,Norfloxacin
,28596959,Maximum plasma concentration (CMAX),Maximum plasma concentration (CMAX) was 4.02 ± 0.31 µg/mL.,Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),[μg] / [ml],4.02,193137,DB01059,Norfloxacin
,28596959,Oral bioavailability,Oral bioavailability of pefloxacin was found to be 70 ± 2%.,Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),%,70,193138,DB01059,Norfloxacin
,28596959,maximal plasma concentration (CMAX),The maximal plasma concentration (CMAX) of N-demethyl pefloxacin (norfloxacin) was calculated as 0.19 ± 0.01 mg/mL.,Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),[mg] / [ml],0.19,193139,DB01059,Norfloxacin
,28596959,t½β,The t½β of N-demethyl pefloxacin after oral pefloxacin administration was 10.93 ± 0.80 h.,Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28596959/),h,10.93,193140,DB01059,Norfloxacin
,16872782,limits of detection,"The limits of detection and quantitation were 6 and 15 ng/mL, respectively.",High-performance liquid chromatography assay for moxifloxacin: pharmacokinetics in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16872782/),[ng] / [ml],6,196052,DB01059,Norfloxacin
,16872782,limits of detection,"The limits of detection and quantitation were 6 and 15 ng/mL, respectively.",High-performance liquid chromatography assay for moxifloxacin: pharmacokinetics in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16872782/),[ng] / [ml],15,196053,DB01059,Norfloxacin
,2920479,bioavailability,"Absorption of norfloxacin, ciprofloxacin, and enoxacin is incomplete, whereas the bioavailability of pefloxacin, ofloxacin and fleroxacin is almost 100%.",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),%,100,197116,DB01059,Norfloxacin
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],1.5,197117,DB01059,Norfloxacin
,2920479,Maximum serum concentrations,Maximum serum concentrations vary between 1.5 and 10.7 micrograms/ml depending on the dose and antibiotic given.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml],10.7,197118,DB01059,Norfloxacin
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],78,197119,DB01059,Norfloxacin
,2920479,AUC's,Respective AUC's of 78 and 5.5 micrograms/ml-h are observed following the administration of 400 mg of either fleroxacin or norfloxacin.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[μg] / [ml-h],5.5,197120,DB01059,Norfloxacin
,2920479,apparent volume of distribution,Protein binding is low (less than or equal to 30%) and apparent volume of distribution is between 1.5 and 3.1 liters/kg.,The pharmacokinetics and tissue penetration of the fluoroquinolones. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),[l] / [kg],1.5 and 3.1,197121,DB01059,Norfloxacin
,2920479,half-lives,"Norfloxacin and ciprofloxacin have the shortest half-lives (+/- 4h), while fleroxacin and pefloxacin have the longest (10-12h).",The pharmacokinetics and tissue penetration of the fluoroquinolones. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920479/),h,10-12,197122,DB01059,Norfloxacin
greater,7735486,resolution factor,The peaks with a resolution factor greater than 1.5 were free from interferences.,Sensitive high-performance liquid chromatographic assay for norfloxacin utilizing fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735486/),,1.5,200138,DB01059,Norfloxacin
,9081960,Time taken to achieve mean peak plasma concentration (Tmax),"Time taken to achieve mean peak plasma concentration (Tmax) was 2.00 +/- 0.74 hours in case of Torrent (A) and 1.70 +/- 0.49 hours in case of Merck Sharp and Dohme, USA (B).",Comparative bioavailability of two brands of norfloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081960/),h,2.00,201195,DB01059,Norfloxacin
,9081960,Time taken to achieve mean peak plasma concentration (Tmax),"Time taken to achieve mean peak plasma concentration (Tmax) was 2.00 +/- 0.74 hours in case of Torrent (A) and 1.70 +/- 0.49 hours in case of Merck Sharp and Dohme, USA (B).",Comparative bioavailability of two brands of norfloxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081960/),h,1.70,201196,DB01059,Norfloxacin
,9081960,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) ranged from 1.60 to 2.87 ug/ml in Torrent (A) and 1.18 to 2.28 ug/ml in case of MSD (B).,Comparative bioavailability of two brands of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081960/),[ug] / [ml],1.60 to 2.87,201197,DB01059,Norfloxacin
,9081960,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) ranged from 1.60 to 2.87 ug/ml in Torrent (A) and 1.18 to 2.28 ug/ml in case of MSD (B).,Comparative bioavailability of two brands of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081960/),[ug] / [ml],1.18 to 2.28,201198,DB01059,Norfloxacin
,9081960,Area under plasma concentration curve (AUCO-12hr),Area under plasma concentration curve (AUCO-12hr) was 12.70 +/- 3.2 ug/ml/hour for 'A' and 14.80 +/- 2.80 ug/ml/hr for 'B'.,Comparative bioavailability of two brands of norfloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081960/),[ug] / [h·ml],12.70,201199,DB01059,Norfloxacin
,9081960,Area under plasma concentration curve (AUCO-12hr),Area under plasma concentration curve (AUCO-12hr) was 12.70 +/- 3.2 ug/ml/hour for 'A' and 14.80 +/- 2.80 ug/ml/hr for 'B'.,Comparative bioavailability of two brands of norfloxacin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081960/),[ug] / [h·ml],14.80,201200,DB01059,Norfloxacin
,9081960,Elimination half life (t1/2),Elimination half life (t1/2) for Torrent (A) was 9.25 +/- 5.10 hours and for MSD (B) it was 12.05 +/- 1.05 hours.,Comparative bioavailability of two brands of norfloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081960/),h,9.25,201201,DB01059,Norfloxacin
,9081960,Elimination half life (t1/2),Elimination half life (t1/2) for Torrent (A) was 9.25 +/- 5.10 hours and for MSD (B) it was 12.05 +/- 1.05 hours.,Comparative bioavailability of two brands of norfloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9081960/),h,12.05,201202,DB01059,Norfloxacin
,15060787,maximum concentration,"The maximum concentration in the aqueous humor of normal rabbit eyes was 2.09 +/- 1.56 microg/ml (60 min, OFLX), 2.57 +/- 1.00 microg/ml (30 min, LVFX), and 0.42 +/- 0.12 microg/ml (120 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],2.09,201865,DB01059,Norfloxacin
,15060787,maximum concentration,"The maximum concentration in the aqueous humor of normal rabbit eyes was 2.09 +/- 1.56 microg/ml (60 min, OFLX), 2.57 +/- 1.00 microg/ml (30 min, LVFX), and 0.42 +/- 0.12 microg/ml (120 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],2.57,201866,DB01059,Norfloxacin
,15060787,maximum concentration,"The maximum concentration in the aqueous humor of normal rabbit eyes was 2.09 +/- 1.56 microg/ml (60 min, OFLX), 2.57 +/- 1.00 microg/ml (30 min, LVFX), and 0.42 +/- 0.12 microg/ml (120 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],0.42,201867,DB01059,Norfloxacin
,15060787,drug concentration,"The drug concentration in the aqueous humor of eyes with intentionally removed corneal epithelium was 12.50 +/- 5.62 microg/ml (30 min, OFLX), 9.02 +/- 2.45 microg/ml (60 min, LVFX), and 8.54 +/- 5.17 microg/ml (30 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],12.50,201868,DB01059,Norfloxacin
,15060787,drug concentration,"The drug concentration in the aqueous humor of eyes with intentionally removed corneal epithelium was 12.50 +/- 5.62 microg/ml (30 min, OFLX), 9.02 +/- 2.45 microg/ml (60 min, LVFX), and 8.54 +/- 5.17 microg/ml (30 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],9.02,201869,DB01059,Norfloxacin
,15060787,drug concentration,"The drug concentration in the aqueous humor of eyes with intentionally removed corneal epithelium was 12.50 +/- 5.62 microg/ml (30 min, OFLX), 9.02 +/- 2.45 microg/ml (60 min, LVFX), and 8.54 +/- 5.17 microg/ml (30 min, NFLX).",The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060787/),[μg] / [ml],8.54,201870,DB01059,Norfloxacin
,2452139,peak norfloxacin concentration,The mean peak norfloxacin concentration in plasma was 1.63 micrograms/ml (range 0.63 to 3.38 micrograms/ml).,Concentrations of norfloxacin in prostatic tissues following oral administration in patients with benign prostatic hyperplasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452139/),[μg] / [ml],1.63,203509,DB01059,Norfloxacin
,2452139,peak concentration,The mean peak concentration in prostatic tissue was 1.63 micrograms/g (range 0.75 to 3.30 micrograms/g).,Concentrations of norfloxacin in prostatic tissues following oral administration in patients with benign prostatic hyperplasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452139/),[μg] / [g],1.63,203510,DB01059,Norfloxacin
,7840566,total body clearance,"The total body clearance values were 4.2 +/- 1.3 (injection during nursing), 1.6 +/- 0.3 (injection 1 day after weaning), and 3.1 +/- 0.8 ml/min/kg (injection 1 month after weaning).",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),[ml] / [kg·min],4.2,209329,DB01059,Norfloxacin
,7840566,total body clearance,"The total body clearance values were 4.2 +/- 1.3 (injection during nursing), 1.6 +/- 0.3 (injection 1 day after weaning), and 3.1 +/- 0.8 ml/min/kg (injection 1 month after weaning).",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),[ml] / [kg·min],1.6,209330,DB01059,Norfloxacin
,7840566,total body clearance,"The total body clearance values were 4.2 +/- 1.3 (injection during nursing), 1.6 +/- 0.3 (injection 1 day after weaning), and 3.1 +/- 0.8 ml/min/kg (injection 1 month after weaning).",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),[ml] / [kg·min],3.1,209331,DB01059,Norfloxacin
,7840566,mean residence times,"The mean residence times were 335 +/- 83, 797 +/- 129, and 481 +/- 102 min and terminal half-lives were 266 +/- 51, 603 +/- 94, and 372 +/- 68 min for the respective treatments.",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),min,335,209332,DB01059,Norfloxacin
,7840566,mean residence times,"The mean residence times were 335 +/- 83, 797 +/- 129, and 481 +/- 102 min and terminal half-lives were 266 +/- 51, 603 +/- 94, and 372 +/- 68 min for the respective treatments.",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),min,797,209333,DB01059,Norfloxacin
,7840566,mean residence times,"The mean residence times were 335 +/- 83, 797 +/- 129, and 481 +/- 102 min and terminal half-lives were 266 +/- 51, 603 +/- 94, and 372 +/- 68 min for the respective treatments.",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),min,481,209334,DB01059,Norfloxacin
,7840566,terminal half-lives,"The mean residence times were 335 +/- 83, 797 +/- 129, and 481 +/- 102 min and terminal half-lives were 266 +/- 51, 603 +/- 94, and 372 +/- 68 min for the respective treatments.",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),min,266,209335,DB01059,Norfloxacin
,7840566,terminal half-lives,"The mean residence times were 335 +/- 83, 797 +/- 129, and 481 +/- 102 min and terminal half-lives were 266 +/- 51, 603 +/- 94, and 372 +/- 68 min for the respective treatments.",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),min,603,209336,DB01059,Norfloxacin
,7840566,terminal half-lives,"The mean residence times were 335 +/- 83, 797 +/- 129, and 481 +/- 102 min and terminal half-lives were 266 +/- 51, 603 +/- 94, and 372 +/- 68 min for the respective treatments.",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),min,372,209337,DB01059,Norfloxacin
,7840566,volumes of distribution at steady state,"The estimated volumes of distribution at steady state were 1.3 +/- 0.1, 1.2 +/- 0.1, and 1.4 +/- 0.2 liter/kg for the respective treatments.",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),[l] / [kg],1.3,209338,DB01059,Norfloxacin
,7840566,volumes of distribution at steady state,"The estimated volumes of distribution at steady state were 1.3 +/- 0.1, 1.2 +/- 0.1, and 1.4 +/- 0.2 liter/kg for the respective treatments.",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),[l] / [kg],1.2,209339,DB01059,Norfloxacin
,7840566,volumes of distribution at steady state,"The estimated volumes of distribution at steady state were 1.3 +/- 0.1, 1.2 +/- 0.1, and 1.4 +/- 0.2 liter/kg for the respective treatments.",Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7840566/),[l] / [kg],1.4,209340,DB01059,Norfloxacin
,2334155,bioavailabilities,"When norfloxacin was given 5 min after Maalox and Titralac, the bioavailabilities were 9.02 and 37.5%, respectively, relative to that for 400 mg of norfloxacin alone.",Inhibition of norfloxacin absorption by antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334155/),%,9.02,215906,DB01059,Norfloxacin
,2334155,bioavailabilities,"When norfloxacin was given 5 min after Maalox and Titralac, the bioavailabilities were 9.02 and 37.5%, respectively, relative to that for 400 mg of norfloxacin alone.",Inhibition of norfloxacin absorption by antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334155/),%,37.5,215907,DB01059,Norfloxacin
,2334155,relative bioavailability,"When Maalox was given 2 h after norfloxacin, maximal concentrations of norfloxacin in plasma occurred between 1 and 1.5 h postdose, and absorption was reduced to a lesser extent, with a relative bioavailability of 81.31%.",Inhibition of norfloxacin absorption by antacids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334155/),%,81.31,215908,DB01059,Norfloxacin
,2611947,recoveries,"The recoveries of norfloxacin, fenbufen and felbinac added to plasma were nearly 100% with a coefficient of variation of less than 8.0%.","High-performance liquid chromatographic procedure for the simultaneous determination of norfloxacin, fenbufen and felbinac in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611947/),%,100,217568,DB01059,Norfloxacin
,24451295,saliva to plasma ratio of INH concentration,The mean saliva to plasma ratio of INH concentration was 0.14.,Isoniazid Pharmacokinetics in the Presence of Ofloxacin and Norfloxacin Antibiotics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24451295/),,0.14,217579,DB01059,Norfloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],11.28,223929,DB01059,Norfloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],6.52,223930,DB01059,Norfloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],13.28,223931,DB01059,Norfloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],3.52,223932,DB01059,Norfloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],4.82,223933,DB01059,Norfloxacin
,9174877,tear concentrations,"Topically applied ciprofloxacin, ofloxacin, and norfloxacin achieved the mean tear concentrations (mean +/- SD) of 11.28 +/- 6.98, 6.52 +/- 4.06, and 13.28 +/- 8.78 micrograms/g at 30 min, and then fell to 3.52 +/- 1.30, 4.82 +/- 1.80, and 5.79 +/- 4.80 micrograms/g at 240 min, respectively.","Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174877/),[μg] / [g],5.79,223934,DB01059,Norfloxacin
,2213972,maximal concentration (Cmax),"The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),,0.96,223940,DB01059,Norfloxacin
,2213972,maximal concentration (Cmax),"The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),,0.99,223941,DB01059,Norfloxacin
,2213972,time to reach maximal concentration (Tmax),"The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),,2.0,223942,DB01059,Norfloxacin
,2213972,elimination constant (Kel),"The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),1/[h],0.101,223943,DB01059,Norfloxacin
,2213972,elimination constant (Kel),"The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),1/[h],0.098,223944,DB01059,Norfloxacin
,2213972,"elimination half life (T1/2, beta)","The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),h,6.909,223945,DB01059,Norfloxacin
,2213972,"elimination half life (T1/2, beta)","The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),h,7.094,223946,DB01059,Norfloxacin
,2213972,absorption constant (Ka),"The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),1/[h],2.444,223947,DB01059,Norfloxacin
,2213972,absorption constant (Ka),"The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),1/[h],2.490,223948,DB01059,Norfloxacin
,2213972,"absorption half life (T1/2, alpha)","The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),h,0.278,223949,DB01059,Norfloxacin
,2213972,"absorption half life (T1/2, alpha)","The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),h,0.277,223950,DB01059,Norfloxacin
,2213972,area under curve (from 0 to 12 hours) (AUC0-12),"The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),h·μg,7.106,223951,DB01059,Norfloxacin
,2213972,area under curve (from 0 to 12 hours) (AUC0-12),"The results revealed that the maximal concentration (Cmax) of Gentle and Baccidal was 0.96 +/- 0.089 and 0.99 +/- 0.110; the time to reach maximal concentration (Tmax) was 2.0 +/- 0.0 for both; the elimination constant (Kel) was 0.101 +/- 0.006 and 0.098 +/- 0.005 hr-1; the elimination half life (T1/2, beta) was 6.909 +/- 0.483 and 7.094 +/- 0.350 hr; the absorption constant (Ka) was 2.444 +/- 0.188 and 2.490 +/- 0.096 hr-1; the absorption half life (T1/2, alpha) was 0.278 +/- 0.019 and 0.277 +/- 0.010 hr; the area under curve (from 0 to 12 hours) (AUC0-12) was 7.106 +/- 1.065 and 7.380 +/- 1.044 micrograms.hr/ml; and the area under curve (from 0 hour to infinity) (AUC0-infinity) was 9.183 +/- 1.257 and 9.550 +/- 1.300 micrograms.hr/ml respectively.",[Comparative study on the pharmacokinetics and bioequivalence of two brands of norfloxacin preparation]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2213972/),h·μg,7.380,223952,DB01059,Norfloxacin
less,2808194,MICs,"The MICs of temafloxacin for 90% of Haemophilus influenzae, Neisseria spp., Enterobacteriaceae, Bacteroides fragilis and Ch. trachomatis were all less than or equal to 1 mg/l, an activity comparable with or superior to that of ofloxacin and superior to those of fleroxacin and norfloxacin.","The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),[mg] / [l],1,229876,DB01059,Norfloxacin
,2808194,peak plasma levels,Mean peak plasma levels of 3.3 mg/l were achieved.,"The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),[mg] / [l],3.3,229877,DB01059,Norfloxacin
,2808194,plasma elimination half life,The mean plasma elimination half life was 6.8 h and the percentage penetration into blister fluid was 104.5%.,"The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),h,6.8,229878,DB01059,Norfloxacin
,2808194,percentage penetration into blister fluid,The mean plasma elimination half life was 6.8 h and the percentage penetration into blister fluid was 104.5%.,"The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2808194/),%,104.5,229879,DB01059,Norfloxacin
,1442075,flow-rate,The flow-rate was 1.0 ml/min and detection was at 294 nm.,[Determination of ofloxacin in human plasma and studies of its pharmacokinetics using HPLC method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442075/),[ml] / [min],1.0,234897,DB01059,Norfloxacin
,1442075,minimal detectable concentration,The minimal detectable concentration in plasma is 20 ng/ml.,[Determination of ofloxacin in human plasma and studies of its pharmacokinetics using HPLC method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442075/),[ng] / [ml],20,234898,DB01059,Norfloxacin
,3169115,maximal,The maximal and minimal steady-state plasma concentrations of amikacin were 27.3 and 3.3 mg/l.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],27.3,238442,DB01059,Norfloxacin
,3169115,minimal steady-state plasma concentrations,The maximal and minimal steady-state plasma concentrations of amikacin were 27.3 and 3.3 mg/l.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],3.3,238443,DB01059,Norfloxacin
,3169115,total plasma clearance,"The total plasma clearance was 83.1 and 67.0 ml/min after the first and the last infusions, respectively, and the half-life was 3.9 and 5.0 h.",Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[ml] / [min],83.1,238444,DB01059,Norfloxacin
,3169115,total plasma clearance,"The total plasma clearance was 83.1 and 67.0 ml/min after the first and the last infusions, respectively, and the half-life was 3.9 and 5.0 h.",Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[ml] / [min],67.0,238445,DB01059,Norfloxacin
,3169115,half-life,"The total plasma clearance was 83.1 and 67.0 ml/min after the first and the last infusions, respectively, and the half-life was 3.9 and 5.0 h.",Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),h,3.9,238446,DB01059,Norfloxacin
,3169115,half-life,"The total plasma clearance was 83.1 and 67.0 ml/min after the first and the last infusions, respectively, and the half-life was 3.9 and 5.0 h.",Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),h,5.0,238447,DB01059,Norfloxacin
,3169115,maximal,The maximal and minimal steady-state plasma concentrations of pefloxacin were 13.1 and 7.9 mg/l after i.v. infusion and 13.4 and 9.0 mg/l after oral administration.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],13.1,238448,DB01059,Norfloxacin
,3169115,maximal,The maximal and minimal steady-state plasma concentrations of pefloxacin were 13.1 and 7.9 mg/l after i.v. infusion and 13.4 and 9.0 mg/l after oral administration.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],13.4,238449,DB01059,Norfloxacin
,3169115,minimal steady-state plasma concentrations,The maximal and minimal steady-state plasma concentrations of pefloxacin were 13.1 and 7.9 mg/l after i.v. infusion and 13.4 and 9.0 mg/l after oral administration.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],7.9,238450,DB01059,Norfloxacin
,3169115,minimal steady-state plasma concentrations,The maximal and minimal steady-state plasma concentrations of pefloxacin were 13.1 and 7.9 mg/l after i.v. infusion and 13.4 and 9.0 mg/l after oral administration.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],9.0,238451,DB01059,Norfloxacin
,3169115,elimination (t1/2),Pefloxacin elimination (t1/2) increased from 11.3 h after the first infusion to 19.4 h after the last infusion and 21.1 h after the last oral dose.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),h,11.3,238452,DB01059,Norfloxacin
,3169115,elimination (t1/2),Pefloxacin elimination (t1/2) increased from 11.3 h after the first infusion to 19.4 h after the last infusion and 21.1 h after the last oral dose.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),h,19.4,238453,DB01059,Norfloxacin
,3169115,elimination (t1/2),Pefloxacin elimination (t1/2) increased from 11.3 h after the first infusion to 19.4 h after the last infusion and 21.1 h after the last oral dose.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),h,21.1,238454,DB01059,Norfloxacin
,3169115,Total body clearance,Total body clearance decreased from 90.8 (Day 1) to 51.9 (Day 5) and 56.4 ml/min (Day 15).,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[ml] / [min],90.8,238455,DB01059,Norfloxacin
,3169115,Total body clearance,Total body clearance decreased from 90.8 (Day 1) to 51.9 (Day 5) and 56.4 ml/min (Day 15).,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[ml] / [min],51.9,238456,DB01059,Norfloxacin
,3169115,Total body clearance,Total body clearance decreased from 90.8 (Day 1) to 51.9 (Day 5) and 56.4 ml/min (Day 15).,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[ml] / [min],56.4,238457,DB01059,Norfloxacin
,3169115,steady-state plasma concentrations,Mean steady-state plasma concentrations of norfloxacin and pefloxacin N-oxide were respectively 0.5-0.6 mg/l and 0.9-1.3 mg/l after intravenous and oral administration of pefloxacin.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],0.5-0.6,238458,DB01059,Norfloxacin
,3169115,steady-state plasma concentrations,Mean steady-state plasma concentrations of norfloxacin and pefloxacin N-oxide were respectively 0.5-0.6 mg/l and 0.9-1.3 mg/l after intravenous and oral administration of pefloxacin.,Pharmacokinetics of pefloxacin and amikacin administered simultaneously to intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3169115/),[mg] / [l],0.9-1.3,238459,DB01059,Norfloxacin
,16359117,limit of detection,The limit of detection for pefloxacin and norfloxacin was 0.03 microg/ml in plasma or microg/g in tissue.,Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),[μg] / [ml],0.03,239906,DB01059,Norfloxacin
,16359117,elimination half-life,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,8.74,239907,DB01059,Norfloxacin
,16359117,time to reach maximum plasma drug concentration,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),[μg] / [ml],3.78,239908,DB01059,Norfloxacin
,16359117,time to reach maximum plasma drug concentration,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,3.33,239909,DB01059,Norfloxacin
,16359117,mean residence time,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,14.32,239910,DB01059,Norfloxacin
,16359117,mean residence time,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,5.66,239911,DB01059,Norfloxacin
,16359117,mean residence time,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),[μg] / [ml],0.80,239912,DB01059,Norfloxacin
,16359117,mean residence time,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,3.67,239913,DB01059,Norfloxacin
,16359117,mean residence time,"The elimination half-life, maximum plasma drug concentration, time to reach maximum plasma drug concentration and mean residence time of pefloxacin were 8.74 +/- 1.48 h, 3.78 +/- 0.23 microg/ml, 3.33 +/- 0.21 h and 14.32 +/- 1.94 h, respectively, whereas the respective values of these variables for norfloxacin were 5.66 +/- 0.81 h, 0.80 +/- 0.07 microg/ml, 3.67 +/- 0.21 h and 14.44 +/- 0.97 h.",Pharmacokinetics and tissue residues of pefloxacin and its metabolite norfloxacin in broiler chickens. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359117/),h,14.44,239914,DB01059,Norfloxacin
,2237915,peak serum concentrations (Cmax),"At these doses, the peak serum concentrations (Cmax) on Day 6 were 16.1, 9.73, and 5.11 micrograms/ml, and the areas under the serum concentration/time curve (AUC0----infinity) were 31.9, 22.9, and 26.2 micrograms.hr/ml, in respective animals.",Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237915/),[μg] / [ml],16.1,242022,DB01059,Norfloxacin
,2237915,peak serum concentrations (Cmax),"At these doses, the peak serum concentrations (Cmax) on Day 6 were 16.1, 9.73, and 5.11 micrograms/ml, and the areas under the serum concentration/time curve (AUC0----infinity) were 31.9, 22.9, and 26.2 micrograms.hr/ml, in respective animals.",Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237915/),[μg] / [ml],9.73,242023,DB01059,Norfloxacin
,2237915,peak serum concentrations (Cmax),"At these doses, the peak serum concentrations (Cmax) on Day 6 were 16.1, 9.73, and 5.11 micrograms/ml, and the areas under the serum concentration/time curve (AUC0----infinity) were 31.9, 22.9, and 26.2 micrograms.hr/ml, in respective animals.",Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237915/),[μg] / [ml],5.11,242024,DB01059,Norfloxacin
,2237915,areas under the serum concentration/time curve (AUC0----infinity),"At these doses, the peak serum concentrations (Cmax) on Day 6 were 16.1, 9.73, and 5.11 micrograms/ml, and the areas under the serum concentration/time curve (AUC0----infinity) were 31.9, 22.9, and 26.2 micrograms.hr/ml, in respective animals.",Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237915/),[h·μg] / [ml],31.9,242025,DB01059,Norfloxacin
,2237915,areas under the serum concentration/time curve (AUC0----infinity),"At these doses, the peak serum concentrations (Cmax) on Day 6 were 16.1, 9.73, and 5.11 micrograms/ml, and the areas under the serum concentration/time curve (AUC0----infinity) were 31.9, 22.9, and 26.2 micrograms.hr/ml, in respective animals.",Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237915/),[h·μg] / [ml],22.9,242026,DB01059,Norfloxacin
,2237915,areas under the serum concentration/time curve (AUC0----infinity),"At these doses, the peak serum concentrations (Cmax) on Day 6 were 16.1, 9.73, and 5.11 micrograms/ml, and the areas under the serum concentration/time curve (AUC0----infinity) were 31.9, 22.9, and 26.2 micrograms.hr/ml, in respective animals.",Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237915/),[h·μg] / [ml],26.2,242027,DB01059,Norfloxacin
,2237915,Cmax,"Monkeys showed no arthropathy with norfloxacin at doses of less than 500 mg/kg/day, at which the Cmax and AUC0----infinity were 15.6 micrograms/ml and 103 micrograms.hr/ml, respectively.",Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237915/),[μg] / [ml],15.6,242028,DB01059,Norfloxacin
,2237915,AUC0----infinity,"Monkeys showed no arthropathy with norfloxacin at doses of less than 500 mg/kg/day, at which the Cmax and AUC0----infinity were 15.6 micrograms/ml and 103 micrograms.hr/ml, respectively.",Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2237915/),[h·μg] / [ml],103,242029,DB01059,Norfloxacin
,8741334,maximum concentration (Cmax),"After instillation, the maximum concentration (Cmax) of NFLX and LFLX in the aqueous humour was 0.80 and 1.20 micrograms/ml, and elimination half time (t1/2) was 130 and 96 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],0.80,242329,DB01059,Norfloxacin
,8741334,maximum concentration (Cmax),"After instillation, the maximum concentration (Cmax) of NFLX and LFLX in the aqueous humour was 0.80 and 1.20 micrograms/ml, and elimination half time (t1/2) was 130 and 96 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],1.20,242330,DB01059,Norfloxacin
,8741334,elimination half time (t1/2),"After instillation, the maximum concentration (Cmax) of NFLX and LFLX in the aqueous humour was 0.80 and 1.20 micrograms/ml, and elimination half time (t1/2) was 130 and 96 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,130,242331,DB01059,Norfloxacin
,8741334,elimination half time (t1/2),"After instillation, the maximum concentration (Cmax) of NFLX and LFLX in the aqueous humour was 0.80 and 1.20 micrograms/ml, and elimination half time (t1/2) was 130 and 96 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,96,242332,DB01059,Norfloxacin
,8741334,Cmax,"After oral administration, the Cmax in plasma of NFLX and LFLX was 2.06 and 1.89 micrograms/ml, and the Cmax in aqueous humour was 0.16 and 0.62 microgram/ml, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],2.06,242333,DB01059,Norfloxacin
,8741334,Cmax,"After oral administration, the Cmax in plasma of NFLX and LFLX was 2.06 and 1.89 micrograms/ml, and the Cmax in aqueous humour was 0.16 and 0.62 microgram/ml, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],1.89,242334,DB01059,Norfloxacin
,8741334,Cmax,"After oral administration, the Cmax in plasma of NFLX and LFLX was 2.06 and 1.89 micrograms/ml, and the Cmax in aqueous humour was 0.16 and 0.62 microgram/ml, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],0.16,242335,DB01059,Norfloxacin
,8741334,Cmax,"After oral administration, the Cmax in plasma of NFLX and LFLX was 2.06 and 1.89 micrograms/ml, and the Cmax in aqueous humour was 0.16 and 0.62 microgram/ml, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),[μg] / [ml],0.62,242336,DB01059,Norfloxacin
,8741334,t1/2,"t1/2 of NFLX in aqueous humour and plasma was 225 and 295 min, and t1/2 of LFLX was 188 and 175 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,225,242337,DB01059,Norfloxacin
,8741334,t1/2,"t1/2 of NFLX in aqueous humour and plasma was 225 and 295 min, and t1/2 of LFLX was 188 and 175 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,295,242338,DB01059,Norfloxacin
,8741334,t1/2,"t1/2 of NFLX in aqueous humour and plasma was 225 and 295 min, and t1/2 of LFLX was 188 and 175 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,188,242339,DB01059,Norfloxacin
,8741334,t1/2,"t1/2 of NFLX in aqueous humour and plasma was 225 and 295 min, and t1/2 of LFLX was 188 and 175 min, respectively.",[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),min,175,242340,DB01059,Norfloxacin
,8741334,ratio of aqueous humour/serum concentration,The ratio of aqueous humour/serum concentration of NFLX and LFLX was 7.8 and 35.3% 4 hrs after oral administration.,[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),,7,242341,DB01059,Norfloxacin
,8741334,ratio of aqueous humour/serum concentration,The ratio of aqueous humour/serum concentration of NFLX and LFLX was 7.8 and 35.3% 4 hrs after oral administration.,[Pharmacokinetics of norfloxacin and lomefloxacin in aqueous humour analysed by microdialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8741334/),,35,242342,DB01059,Norfloxacin
,3286510,amounts,"The amounts of unchanged drug excreted in urine (48 h period) were found to be 35%, 24% and 77% for ciprofloxacin, norfloxacin and ofloxacin respectively, indicating different excretion kinetics.","Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286510/),%,35,245079,DB01059,Norfloxacin
,3286510,amounts,"The amounts of unchanged drug excreted in urine (48 h period) were found to be 35%, 24% and 77% for ciprofloxacin, norfloxacin and ofloxacin respectively, indicating different excretion kinetics.","Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286510/),%,24,245080,DB01059,Norfloxacin
,3286510,amounts,"The amounts of unchanged drug excreted in urine (48 h period) were found to be 35%, 24% and 77% for ciprofloxacin, norfloxacin and ofloxacin respectively, indicating different excretion kinetics.","Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3286510/),%,77,245081,DB01059,Norfloxacin
,16434544,plasma concentration,"In vivo pharmacokinetic studies showed that the ciprofloxacin plasma concentration was more than 2-fold increased in Bcrp1(-/-) compared with wild-type mice (1.77 +/- 0.73 versus 0.85 +/- 0.39 microg/ml, p < 0.01) after oral administration of ciprofloxacin (10 mg/kg).","Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16434544/),,1,253324,DB01059,Norfloxacin
,16434544,plasma concentration,"In vivo pharmacokinetic studies showed that the ciprofloxacin plasma concentration was more than 2-fold increased in Bcrp1(-/-) compared with wild-type mice (1.77 +/- 0.73 versus 0.85 +/- 0.39 microg/ml, p < 0.01) after oral administration of ciprofloxacin (10 mg/kg).","Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16434544/),,0.85,253325,DB01059,Norfloxacin
,16434544,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve in Bcrp1(-/-) mice was 1.5-fold higher than that in wild-type mice (48.63 +/- 5.66 versus 33.10 +/- 4.68 min x microg/ml, p < 0.05) after i.v. administration (10 mg/kg).","Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16434544/),[min·μg] / [ml],48.63,253326,DB01059,Norfloxacin
,16434544,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve in Bcrp1(-/-) mice was 1.5-fold higher than that in wild-type mice (48.63 +/- 5.66 versus 33.10 +/- 4.68 min x microg/ml, p < 0.05) after i.v. administration (10 mg/kg).","Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16434544/),[min·μg] / [ml],33.10,253327,DB01059,Norfloxacin
,4055162,Serum half-life,"Serum half-life in controls was 3.87 hours and prolonged to 5.85 hours in group I (creatinine clearance 80-45 ml/min), 7.25 hours (p less than 0.05) in group II (creatinine clearance 44-20 ml/min) and 8.34 hours (p less than 0.01) in group III patients (creatinine clearance less than 20 ml/min).",Pharmacokinetics of norfloxacin in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4055162/),h,3.87,254996,DB01059,Norfloxacin
,4055162,Serum half-life,"Serum half-life in controls was 3.87 hours and prolonged to 5.85 hours in group I (creatinine clearance 80-45 ml/min), 7.25 hours (p less than 0.05) in group II (creatinine clearance 44-20 ml/min) and 8.34 hours (p less than 0.01) in group III patients (creatinine clearance less than 20 ml/min).",Pharmacokinetics of norfloxacin in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4055162/),h,5.85,254997,DB01059,Norfloxacin
,4055162,Serum half-life,"Serum half-life in controls was 3.87 hours and prolonged to 5.85 hours in group I (creatinine clearance 80-45 ml/min), 7.25 hours (p less than 0.05) in group II (creatinine clearance 44-20 ml/min) and 8.34 hours (p less than 0.01) in group III patients (creatinine clearance less than 20 ml/min).",Pharmacokinetics of norfloxacin in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4055162/),h,7.25,254998,DB01059,Norfloxacin
,4055162,Serum half-life,"Serum half-life in controls was 3.87 hours and prolonged to 5.85 hours in group I (creatinine clearance 80-45 ml/min), 7.25 hours (p less than 0.05) in group II (creatinine clearance 44-20 ml/min) and 8.34 hours (p less than 0.01) in group III patients (creatinine clearance less than 20 ml/min).",Pharmacokinetics of norfloxacin in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4055162/),h,8.34,254999,DB01059,Norfloxacin
,3865778,volume of distribution (Vd area),"The mean volume of distribution (Vd area) and the mean plasma clearance were 2.03 l X kg-1 and 121.3 ml X min-1, respectively.",Pharmacokinetics of pefloxacin in renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865778/),[l] / [kg],2.03,257172,DB01059,Norfloxacin
,3865778,plasma clearance,"The mean volume of distribution (Vd area) and the mean plasma clearance were 2.03 l X kg-1 and 121.3 ml X min-1, respectively.",Pharmacokinetics of pefloxacin in renal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865778/),[ml] / [min],121.3,257173,DB01059,Norfloxacin
,3865778,apparent elimination half-life,The mean apparent elimination half-life was 13.5 h.,Pharmacokinetics of pefloxacin in renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865778/),h,13.5,257174,DB01059,Norfloxacin
,23817346,saliva to plasma ratio,The mean saliva to plasma ratio of RIF concentration was approximately 0.15.,Effect of ofloxacin and norfloxacin on rifampicin pharmacokinetics in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23817346/),,0.15,262548,DB01059,Norfloxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],3.19 x 10(4),263673,DB01059,Norfloxacin
,17159308,binding constants,The yield binding constants were between 3.19 x 10(4) and 1.21 x 10(5) M(-1).,Interaction between fluoroquinolones and bovine serum albumin studied by affinity capillary electrophoresis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17159308/),1/[M],1.21 x 10(5),263674,DB01059,Norfloxacin
,18520606,recoveries,"The recoveries at concentrations of 90, 1400, and 2800 ng/mL were 103.5%, 100.2%, and 100.2%, respectively.",Validation of a reversed-phase high-performance liquid chromatography method with fluorescence detection for the bioequivalence study of norfloxacin in plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520606/),%,1400,266073,DB01059,Norfloxacin
,18520606,recoveries,"The recoveries at concentrations of 90, 1400, and 2800 ng/mL were 103.5%, 100.2%, and 100.2%, respectively.",Validation of a reversed-phase high-performance liquid chromatography method with fluorescence detection for the bioequivalence study of norfloxacin in plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520606/),%,280,266074,DB01059,Norfloxacin
,18520606,recoveries,"The recoveries at concentrations of 90, 1400, and 2800 ng/mL were 103.5%, 100.2%, and 100.2%, respectively.",Validation of a reversed-phase high-performance liquid chromatography method with fluorescence detection for the bioequivalence study of norfloxacin in plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520606/),%,103.5,266075,DB01059,Norfloxacin
,18520606,recoveries,"The recoveries at concentrations of 90, 1400, and 2800 ng/mL were 103.5%, 100.2%, and 100.2%, respectively.",Validation of a reversed-phase high-performance liquid chromatography method with fluorescence detection for the bioequivalence study of norfloxacin in plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520606/),%,100.2,266076,DB01059,Norfloxacin
,29552066,AUC,"The AUC and Cmax of NFX alone were 6.0 µg.hr/mL (2.3-9.8) and 0.87 µg/mL (0.4-1.6), respectively whereas the corresponding AUC and Cmax values after administration of FDC were 7.1 µg.hr/mL (4.0-10.6) and 0.97 µg/mL (0.4-1.7), respectively.",Effect of Tinidazole on Norfloxacin Disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29552066/),[h·μg] / [ml],6.0,270206,DB01059,Norfloxacin
,29552066,Cmax,"The AUC and Cmax of NFX alone were 6.0 µg.hr/mL (2.3-9.8) and 0.87 µg/mL (0.4-1.6), respectively whereas the corresponding AUC and Cmax values after administration of FDC were 7.1 µg.hr/mL (4.0-10.6) and 0.97 µg/mL (0.4-1.7), respectively.",Effect of Tinidazole on Norfloxacin Disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29552066/),[μg] / [ml],0.87,270207,DB01059,Norfloxacin
,29552066,AUC,"The AUC and Cmax of NFX alone were 6.0 µg.hr/mL (2.3-9.8) and 0.87 µg/mL (0.4-1.6), respectively whereas the corresponding AUC and Cmax values after administration of FDC were 7.1 µg.hr/mL (4.0-10.6) and 0.97 µg/mL (0.4-1.7), respectively.",Effect of Tinidazole on Norfloxacin Disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29552066/),[h·μg] / [ml],7.1,270208,DB01059,Norfloxacin
,29552066,Cmax,"The AUC and Cmax of NFX alone were 6.0 µg.hr/mL (2.3-9.8) and 0.87 µg/mL (0.4-1.6), respectively whereas the corresponding AUC and Cmax values after administration of FDC were 7.1 µg.hr/mL (4.0-10.6) and 0.97 µg/mL (0.4-1.7), respectively.",Effect of Tinidazole on Norfloxacin Disposition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29552066/),[μg] / [ml],0.97,270209,DB01059,Norfloxacin
,3463542,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax 1.2 h) and enoxacin the least (Tmax 1.9 h).,The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,1.2,271330,DB01059,Norfloxacin
,3463542,Tmax,Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax 1.2 h) and enoxacin the least (Tmax 1.9 h).,The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,1.9,271331,DB01059,Norfloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,3.75,271332,DB01059,Norfloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,3.9,271333,DB01059,Norfloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,4.0,271334,DB01059,Norfloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,7.0,271335,DB01059,Norfloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,6.2,271336,DB01059,Norfloxacin
,3463542,serum half-lives,"The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (p.o.), 4.0 h (i.v.), ofloxacin 7.0 h and enoxacin 6.2 h (p.o.) and 5.1 h (i.v.).",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),h,5.1,271337,DB01059,Norfloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,62,271338,DB01059,Norfloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,46.4,271339,DB01059,Norfloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,11.6,271340,DB01059,Norfloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,27,271341,DB01059,Norfloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,30.6,271342,DB01059,Norfloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,75.7,271343,DB01059,Norfloxacin
,3463542,urine recovery,"The 24 h urine recovery (as measured by a microbiological assay) was 62% for enoxacin (p.o.), 46.4% following i.v. enoxacin (plus 11.6% oxo-enoxacin, measured by HPLC) 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for i.v. ciprofloxacin and 73% for ofloxacin.",The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463542/),%,73,271344,DB01059,Norfloxacin
,22293231,oral bioavailability,Its oral bioavailability is 30-40% and is a case for improvement by appropriate formulation design.,Development of sustained release floating drug delivery system for norfloxacin: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22293231/),%,30-40,272886,DB01059,Norfloxacin
,22293231,increased bioavailability,The increased bioavailability of developed formulation was found to be 16.27%.,Development of sustained release floating drug delivery system for norfloxacin: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22293231/),%,16.27,272887,DB01059,Norfloxacin
,22293231,increased bioavailability,The increased bioavailability of the developed formulation was found to be 16.27%.,Development of sustained release floating drug delivery system for norfloxacin: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22293231/),%,16.27,272888,DB01059,Norfloxacin
